Samsara Inc.79589L106US79589L106107/10/2024Election of Directors: Sanjit BiswasDIRECTOR ELECTIONSISSUER9479052.0000000FOR9479052.000000FORS000002106Samsara Inc.79589L106US79589L106107/10/2024Election of Directors: John BicketDIRECTOR ELECTIONSISSUER9479052.0000000FOR9479052.000000FORS000002106Samsara Inc.79589L106US79589L106107/10/2024Election of Directors: Marc AndreessenDIRECTOR ELECTIONSISSUER9479052.0000000FOR9479052.000000FORS000002106Samsara Inc.79589L106US79589L106107/10/2024Election of Directors: Todd BluedornDIRECTOR ELECTIONSISSUER9479052.0000000FOR9479052.000000FORS000002106Samsara Inc.79589L106US79589L106107/10/2024Election of Directors: Sue BostromDIRECTOR ELECTIONSISSUER9479052.0000000FOR9479052.000000FORS000002106Samsara Inc.79589L106US79589L106107/10/2024Election of Directors: Jonathan ChadwickDIRECTOR ELECTIONSISSUER9479052.0000000FOR9479052.000000FORS000002106Samsara Inc.79589L106US79589L106107/10/2024Election of Directors: Ann LivermoreDIRECTOR ELECTIONSISSUER9479052.0000000FOR9479052.000000FORS000002106Samsara Inc.79589L106US79589L106107/10/2024Election of Directors: Sue WagnerDIRECTOR ELECTIONSISSUER9479052.0000000FOR9479052.000000FORS000002106Samsara Inc.79589L106US79589L106107/10/2024The ratification of the appointment of Deloitte & Touche LLP as Samsara Inc.'s independent registered public accounting firm for the fiscal year ending February 1, 2025.AUDIT-RELATEDISSUER9479052.0000000FOR9479052.000000FORS000002106Samsara Inc.79589L106US79589L106107/10/2024The approval, on a non-binding advisory basis, of the compensation of Samsara Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER9479052.0000000AGAINST9479052.000000AGAINSTS000002106ICON plcG4705A100IE000571120907/23/2024Elect Director Ciaran MurrayDIRECTOR ELECTIONSISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Elect Director Steve CutlerDIRECTOR ELECTIONSISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Elect Director Ronan MurphyDIRECTOR ELECTIONSISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Elect Director John ClimaxDIRECTOR ELECTIONSISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Elect Director Julie O'NeillDIRECTOR ELECTIONSISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Elect Director Eugene McCagueDIRECTOR ELECTIONSISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Elect Director Linda GraisDIRECTOR ELECTIONSISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Authorise Board to Fix Remuneration of AuditorsAUDIT-RELATEDISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Authorise Issue of EquityCAPITAL STRUCTUREISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Authorise Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Authorize Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital InvestmentCAPITAL STRUCTUREISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Authorise Market Purchase of Ordinary SharesCAPITAL STRUCTUREISSUER976700.0000000FOR976700.000000FORS000002106ICON plcG4705A100IE000571120907/23/2024Approve the Price Range for the Reissuance of SharesCAPITAL STRUCTUREISSUER976700.0000000FOR976700.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: Horacio D. RozanskiDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: Joan Lordi C. AmbleDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: Melody C. BarnesDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: Michele A. FlournoyDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: Mark GaumondDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: Ellen JewettDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: Arthur E. JohnsonDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: Gretchen W. McClainDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: Rory P. ReadDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: Charles O. RossottiDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Election of Directors: William M. ThornberryDIRECTOR ELECTIONSISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Ratification of the appointment of Ernst & Young LLP as the Company's registered independent public accountants for fiscal year 2025.AUDIT-RELATEDISSUER3438653.0000000FOR3438653.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/24/2024Advisory vote to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3438653.0000000FOR3438653.000000FORS000002106monday.com Ltd.M7S64H106IL001176213007/31/2024Reelect Jeff Horing as DirectorDIRECTOR ELECTIONSISSUER1567338.0000000FOR1567338.000000FORS000002106monday.com Ltd.M7S64H106IL001176213007/31/2024Reelect Avishai Abrahami as DirectorDIRECTOR ELECTIONSISSUER1567338.0000000FOR1567338.000000FORS000002106monday.com Ltd.M7S64H106IL001176213007/31/2024Reappoint Brightman, Almagor and Zohar as Auditors and Authorize Board to Fix Their RemunerationAUDIT-RELATEDISSUER1567338.0000000FOR1567338.000000FORS000002106Immunovant, Inc.45258J102US45258J102508/12/2024To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Peter Salzmann, M.D., M.B.A.DIRECTOR ELECTIONSISSUER801056.0000000WITHHOLD801056.000000AGAINSTS000002106Immunovant, Inc.45258J102US45258J102508/12/2024To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: George MigauskyDIRECTOR ELECTIONSISSUER801056.0000000WITHHOLD801056.000000AGAINSTS000002106Immunovant, Inc.45258J102US45258J102508/12/2024To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas HughesDIRECTOR ELECTIONSISSUER801056.0000000WITHHOLD801056.000000AGAINSTS000002106Immunovant, Inc.45258J102US45258J102508/12/2024To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2025.AUDIT-RELATEDISSUER801056.0000000FOR801056.000000FORS000002106Immunovant, Inc.45258J102US45258J102508/12/2024To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER801056.0000000FOR801056.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/22/2024To elect three Class II directors to serve a three-year term expiring at our 2027 annual meeting of stockholders: Tiffany DanieleDIRECTOR ELECTIONSISSUER336277.0000000FOR336277.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/22/2024To elect three Class II directors to serve a three-year term expiring at our 2027 annual meeting of stockholders: Maria FerrerasDIRECTOR ELECTIONSISSUER336277.0000000FOR336277.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/22/2024To elect three Class II directors to serve a three-year term expiring at our 2027 annual meeting of stockholders: Lauren Cooks LevitanDIRECTOR ELECTIONSISSUER336277.0000000FOR336277.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/22/2024To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to provide for officer exculpation.CORPORATE GOVERNANCEISSUER336277.0000000FOR336277.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/22/2024To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER336277.0000000FOR336277.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/22/2024To ratify the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2025.AUDIT-RELATEDISSUER336277.0000000FOR336277.000000FORS000002106Replimune Group, Inc.76029N106US76029N106309/04/2024Election of Directors: Sushil PatelDIRECTOR ELECTIONSISSUER4408434.0000000FOR4408434.000000FORS000002106Replimune Group, Inc.76029N106US76029N106309/04/2024Election of Directors: Dieter WeinandDIRECTOR ELECTIONSISSUER4408434.0000000FOR4408434.000000FORS000002106Replimune Group, Inc.76029N106US76029N106309/04/2024Election of Directors: Madhavan BalachandranDIRECTOR ELECTIONSISSUER4408434.0000000FOR4408434.000000FORS000002106Replimune Group, Inc.76029N106US76029N106309/04/2024To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Replimune Group, Inc. for the fiscal year ending March 31, 2025.AUDIT-RELATEDISSUER4408434.0000000FOR4408434.000000FORS000002106Replimune Group, Inc.76029N106US76029N106309/04/2024To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4408434.0000000FOR4408434.000000FORS000002106Replimune Group, Inc.76029N106US76029N106309/04/2024To approve, on a non-binding advisory basis, the preferred frequency of future advisory votes on the compensation of Replimune Group, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4408434.0000000ONE YEAR4408434.000000FORS000002106RBC Bearings Incorporated75524B104US75524B104409/05/2024Election of Class II Directors to serve a term of three years: Richard R. CrowellDIRECTOR ELECTIONSISSUER1221581.0000000AGAINST1221581.000000AGAINSTS000002106RBC Bearings Incorporated75524B104US75524B104409/05/2024Election of Class II Directors to serve a term of three years: Dr. Amir FaghriDIRECTOR ELECTIONSISSUER1221581.0000000AGAINST1221581.000000AGAINSTS000002106RBC Bearings Incorporated75524B104US75524B104409/05/2024Election of Class II Directors to serve a term of three years: Dr. Steven H. KaplanDIRECTOR ELECTIONSISSUER1221581.0000000AGAINST1221581.000000AGAINSTS000002106RBC Bearings Incorporated75524B104US75524B104409/05/2024To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal 2025.AUDIT-RELATEDISSUER1221581.0000000FOR1221581.000000FORS000002106RBC Bearings Incorporated75524B104US75524B104409/05/2024To approve the amendment of the certificate of incorporation to eliminate personal liability of officers for monetary damages for breach of their fiduciary duty of care as officers to the fullest extent permitted by the Delaware General Corporation Law.CORPORATE GOVERNANCEISSUER1221581.0000000FOR1221581.000000FORS000002106RBC Bearings Incorporated75524B104US75524B104409/05/2024To consider a resolution regarding the stockholder advisory vote on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1221581.0000000FOR1221581.000000FORS000002106StepStone Group Inc.85914M107US85914M107109/10/2024To elect the five director nominees named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, removal, retirement or disqualification: Monte M. BremDIRECTOR ELECTIONSISSUER719038.0000000WITHHOLD719038.000000AGAINSTS000002106StepStone Group Inc.85914M107US85914M107109/10/2024To elect the five director nominees named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, removal, retirement or disqualification: Valerie G. BrownDIRECTOR ELECTIONSISSUER719038.0000000FOR719038.000000FORS000002106StepStone Group Inc.85914M107US85914M107109/10/2024To elect the five director nominees named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, removal, retirement or disqualification: Scott W. HartDIRECTOR ELECTIONSISSUER719038.0000000FOR719038.000000FORS000002106StepStone Group Inc.85914M107US85914M107109/10/2024To elect the five director nominees named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, removal, retirement or disqualification: David F. HoffmeisterDIRECTOR ELECTIONSISSUER719038.0000000FOR719038.000000FORS000002106StepStone Group Inc.85914M107US85914M107109/10/2024To elect the five director nominees named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, removal, retirement or disqualification: Anne L. RaymondDIRECTOR ELECTIONSISSUER719038.0000000FOR719038.000000FORS000002106StepStone Group Inc.85914M107US85914M107109/10/2024To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2025.AUDIT-RELATEDISSUER719038.0000000FOR719038.000000FORS000002106StepStone Group Inc.85914M107US85914M107109/10/2024To approve, on a non-binding and advisory basis, the compensation of our named executive officers ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER719038.0000000FOR719038.000000FORS000002106StepStone Group Inc.85914M107US85914M107109/10/2024To approve, for purposes of complying with Nasdaq Listing Rule 5635, the issuance of shares of the Company's Class A common stock pursuant to the terms of the Option Agreement, dated November 2, 2022, between the Company and the other parties thereto.CAPITAL STRUCTUREISSUER719038.0000000FOR719038.000000FORS000002106Legend Biotech Corporation52490G102US52490G102210/21/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER384813.0000000FOR384813.000000FORS000002106Legend Biotech Corporation52490G102US52490G102210/21/2024Ratify Ernst & Young LLP as AuditorsAUDIT-RELATEDISSUER384813.0000000FOR384813.000000FORS000002106Legend Biotech Corporation52490G102US52490G102210/21/2024Elect Director Ye WangDIRECTOR ELECTIONSISSUER384813.0000000AGAINST384813.000000AGAINSTS000002106Legend Biotech Corporation52490G102US52490G102210/21/2024Elect Director Darren Xiaohui JiDIRECTOR ELECTIONSISSUER384813.0000000FOR384813.000000FORS000002106Legend Biotech Corporation52490G102US52490G102210/21/2024Elect Director Ying HuangDIRECTOR ELECTIONSISSUER384813.0000000FOR384813.000000FORS000002106Legend Biotech Corporation52490G102US52490G102210/21/2024Elect Director Tomas HeymanDIRECTOR ELECTIONSISSUER384813.0000000FOR384813.000000FORS000002106Legend Biotech Corporation52490G102US52490G102210/21/2024Amend Restricted Stock PlanCOMPENSATIONISSUER384813.0000000FOR384813.000000FORS000002106Legend Biotech Corporation52490G102US52490G102210/21/2024Authorize Board to Ratify and Execute Approved ResolutionsCORPORATE GOVERNANCEISSUER384813.0000000FOR384813.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024To set the number of Directors at nine.CORPORATE GOVERNANCEISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Robert V. BaumgartnerDIRECTOR ELECTIONSISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Julie L. BushmanDIRECTOR ELECTIONSISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Judith KlimovskyDIRECTOR ELECTIONSISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: John L. HigginsDIRECTOR ELECTIONSISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Kim KeldermanDIRECTOR ELECTIONSISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Alpna SethDIRECTOR ELECTIONSISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Rupert VesseyDIRECTOR ELECTIONSISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Joseph D. KeeganDIRECTOR ELECTIONSISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Roeland NusseDIRECTOR ELECTIONSISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Approve, on an advisory basis, the compensation of our executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5722579.0000000FOR5722579.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/24/2024Ratify the appointment of KPMG, LLP as the Company's independent registered public accounting firm for the 2025 fiscal year.AUDIT-RELATEDISSUER5722579.0000000FOR5722579.000000FORS000002106Bill Holdings, Inc.090043100US090043100012/05/2024To elect the directors listed below: Aida AlvarezDIRECTOR ELECTIONSISSUER5887829.0000000WITHHOLD74186.743430AGAINSTFOR5813642.256570FORS000002106Bill Holdings, Inc.090043100US090043100012/05/2024To elect the directors listed below: Steve FisherDIRECTOR ELECTIONSISSUER5887829.0000000WITHHOLD588.783680AGAINSTFOR5887240.216320FORS000002106Bill Holdings, Inc.090043100US090043100012/05/2024To elect the directors listed below: Allison MnookinDIRECTOR ELECTIONSISSUER5887829.0000000WITHHOLD52990.531020AGAINSTFOR5834838.468980FORS000002106Bill Holdings, Inc.090043100US090043100012/05/2024To elect the directors listed below: Alison WagonfeldDIRECTOR ELECTIONSISSUER5887829.0000000WITHHOLD51812.963670AGAINSTFOR5836016.036330FORS000002106Bill Holdings, Inc.090043100US090043100012/05/2024To ratify the appointment of PricewaterhouseCoopers LLP as our Independent Registered Public Accounting Firm for the Fiscal Year ending June 30, 2025.AUDIT-RELATEDISSUER5887829.0000000AGAINST588.783680AGAINSTFOR5887240.216320FORS000002106Bill Holdings, Inc.090043100US090043100012/05/2024To approve, on an advisory basis, the compensation of our Named Executive Officers (Say-on-Pay).SECTION 14A SAY-ON-PAY VOTESISSUER5887829.0000000AGAINST125410.923420AGAINSTFOR5762418.076580FORS000002106Bill Holdings, Inc.090043100US090043100012/05/2024To approve an amendment to our Restated Certificate of Incorporation to limit the liability of certain officers as permitted pursuant to recent amendments to the Delaware General Corporation Law.CORPORATE GOVERNANCEISSUER5887829.0000000AGAINST20607.428730AGAINSTFOR5867221.571270FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Election of Directors: Steven R. BeauchampDIRECTOR ELECTIONSISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Election of Directors: Linda M. BreardDIRECTOR ELECTIONSISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Election of Directors: Virginia G. BreenDIRECTOR ELECTIONSISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Election of Directors: Craig A. ConwayDIRECTOR ELECTIONSISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Election of Directors: Robin L. PedersonDIRECTOR ELECTIONSISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Election of Directors: Andres D. ReinerDIRECTOR ELECTIONSISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Election of Directors: Kenneth B. RobinsonDIRECTOR ELECTIONSISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Election of Directors: Steven I. SarowitzDIRECTOR ELECTIONSISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Election of Directors: Ronald V. Waters IIIDIRECTOR ELECTIONSISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Election of Directors: Toby J. WilliamsDIRECTOR ELECTIONSISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2025.AUDIT-RELATEDISSUER3318574.0000000FOR3318574.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106112/05/2024Advisory vote to approve the compensation of named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3318574.0000000FOR3318574.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/06/2025The election of five directors nominated by our board of directors and named in the accompanying proxy materials to serve until the 2026 annual meeting of stockholders: Peter ChungDIRECTOR ELECTIONSISSUER2495680.0000000FOR2495680.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/06/2025The election of five directors nominated by our board of directors and named in the accompanying proxy materials to serve until the 2026 annual meeting of stockholders: Geoffrey RibarDIRECTOR ELECTIONSISSUER2495680.0000000FOR2495680.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/06/2025The election of five directors nominated by our board of directors and named in the accompanying proxy materials to serve until the 2026 annual meeting of stockholders: John RitchieDIRECTOR ELECTIONSISSUER2495680.0000000FOR2495680.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/06/2025The election of five directors nominated by our board of directors and named in the accompanying proxy materials to serve until the 2026 annual meeting of stockholders: Jihye Whang RosenbandDIRECTOR ELECTIONSISSUER2495680.0000000FOR2495680.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/06/2025The election of five directors nominated by our board of directors and named in the accompanying proxy materials to serve until the 2026 annual meeting of stockholders: Murugesan "Raj" ShanmugarajDIRECTOR ELECTIONSISSUER2495680.0000000FOR2495680.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/06/2025Advisory vote to approve the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2495680.0000000FOR2495680.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/06/2025Advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2495680.0000000ONE YEAR2495680.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/06/2025Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending October 3, 2025AUDIT-RELATEDISSUER2495680.0000000FOR2495680.000000FORS000002106The Toro Company891092108US891092108403/18/2025Election of Directors: Jeff L. HarmeningDIRECTOR ELECTIONSISSUER3644480.0000000WITHHOLD3644480.000000AGAINSTS000002106The Toro Company891092108US891092108403/18/2025Election of Directors: Joyce A. MullenDIRECTOR ELECTIONSISSUER3644480.0000000WITHHOLD3644480.000000AGAINSTS000002106The Toro Company891092108US891092108403/18/2025Election of Directors: Richard M. OlsonDIRECTOR ELECTIONSISSUER3644480.0000000FOR3644480.000000FORS000002106The Toro Company891092108US891092108403/18/2025Election of Directors: James C. O'RourkeDIRECTOR ELECTIONSISSUER3644480.0000000WITHHOLD3644480.000000AGAINSTS000002106The Toro Company891092108US891092108403/18/2025Ratification of the selection of KPMG LLP as our independent registered public accounting firm for our fiscal year ending October 31, 2025.AUDIT-RELATEDISSUER3644480.0000000FOR3644480.000000FORS000002106The Toro Company891092108US891092108403/18/2025Approval of, on an advisory basis, our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER3644480.0000000FOR3644480.000000FORS000002106Moncler SpAT6730E110IT000496514803/20/2025Amend Company Bylaws Re: Articles 13, 14, 15, 19, and 24CORPORATE GOVERNANCEISSUER473099.0000000FOR473099.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Amend Article 15.3 of Bylaws Re: Directors Length of TermCORPORATE GOVERNANCEISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Amend Article 17.5 of Bylaws Re: Virtual ParticipationCORPORATE GOVERNANCEISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Financial Statements and Discharge DirectorsCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Allocation of Income and Dividends of EUR 0.69 per ShareCAPITAL STRUCTUREISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Remuneration Policy of Directors; Approve Remuneration of Directors in the Aggregate Amount of EUR 640,000COMPENSATIONISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Compensation Report of Corporate OfficersCOMPENSATIONISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Compensation of Chairman of the BoardCOMPENSATIONISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Compensation of CEOCOMPENSATIONISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Remuneration Policy of Chairman of the BoardCOMPENSATIONISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Remuneration Policy of CEOCOMPENSATIONISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Reelect Joachim Kreuzburg as DirectorDIRECTOR ELECTIONSISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Reelect Rene Faber as DirectorDIRECTOR ELECTIONSISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Reelect Pascale Boissel as DirectorDIRECTOR ELECTIONSISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Reelect Lothar Kappich as DirectorDIRECTOR ELECTIONSISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Elect Christopher Nowers as DirectorDIRECTOR ELECTIONSISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Elect Cecile Dussart as DirectorDIRECTOR ELECTIONSISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Authorize Repurchase of Up to 0.10 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights (Rights Issue) up to Aggregate Nominal Amount of EUR 6 MillionCAPITAL STRUCTUREISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 6 MillionCAPITAL STRUCTUREISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Issuance of Equity or Equity-Linked Securities Reserved for Qualified Investors, up to Aggregate Nominal Amount of EUR 6 MillionCAPITAL STRUCTUREISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 163,464.4CAPITAL STRUCTUREISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote AboveCAPITAL STRUCTUREISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Authorize Capital Increase of up to 20 Percent of Issued Capital for Contributions in KindCAPITAL STRUCTUREISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Authorize Capitalization of Reserves of Up to EUR 6 Million for Bonus Issue or Increase in Par ValueCAPITAL STRUCTUREISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Authorize Capital Issuances for Use in Employee Stock Purchase PlansCOMPENSATIONISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock PlansCOMPENSATIONISSUER203197.0000000FOR203197.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/25/2025Authorize Decrease in Share Capital via Cancellation of Repurchased SharesCAPITAL STRUCTUREISSUER203197.0000000FOR203197.000000FORS000002106FirstService Corporation33767E202CA33767E202404/02/2025Elect Director Yousry BissadaDIRECTOR ELECTIONSISSUER449281.0000000FOR449281.000000FORS000002106FirstService Corporation33767E202CA33767E202404/02/2025Elect Director Elizabeth CarducciDIRECTOR ELECTIONSISSUER449281.0000000FOR449281.000000FORS000002106FirstService Corporation33767E202CA33767E202404/02/2025Elect Director Steve H. GrimshawDIRECTOR ELECTIONSISSUER449281.0000000FOR449281.000000FORS000002106FirstService Corporation33767E202CA33767E202404/02/2025Elect Director Jay S. HennickDIRECTOR ELECTIONSISSUER449281.0000000FOR449281.000000FORS000002106FirstService Corporation33767E202CA33767E202404/02/2025Elect Director D. Scott PattersonDIRECTOR ELECTIONSISSUER449281.0000000FOR449281.000000FORS000002106FirstService Corporation33767E202CA33767E202404/02/2025Elect Director Frederick F. ReichheldDIRECTOR ELECTIONSISSUER449281.0000000FOR449281.000000FORS000002106FirstService Corporation33767E202CA33767E202404/02/2025Elect Director Joan Eloise SproulDIRECTOR ELECTIONSISSUER449281.0000000FOR449281.000000FORS000002106FirstService Corporation33767E202CA33767E202404/02/2025Elect Director Erin J. WallaceDIRECTOR ELECTIONSISSUER449281.0000000FOR449281.000000FORS000002106FirstService Corporation33767E202CA33767E202404/02/2025Approve PricewaterhouseCoopers LLP as Auditors and Authorize Board to Fix Their RemunerationAUDIT-RELATEDISSUER449281.0000000FOR449281.000000FORS000002106FirstService Corporation33767E202CA33767E202404/02/2025Advisory Vote on Executive Compensation ApproachCOMPENSATIONISSUER449281.0000000FOR449281.000000FORS000002106The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Robert S. WeissDIRECTOR ELECTIONSISSUER921342.0000000FOR921342.000000FORS000002106The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Colleen E. JayDIRECTOR ELECTIONSISSUER921342.0000000FOR921342.000000FORS000002106The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Lawrence E. KurziusDIRECTOR ELECTIONSISSUER921342.0000000FOR921342.000000FORS000002106The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Cynthia L. LuccheseDIRECTOR ELECTIONSISSUER921342.0000000FOR921342.000000FORS000002106The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Teresa S. MaddenDIRECTOR ELECTIONSISSUER921342.0000000FOR921342.000000FORS000002106The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Maria Rivas, M.D.DIRECTOR ELECTIONSISSUER921342.0000000FOR921342.000000FORS000002106The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Albert G. White IIIDIRECTOR ELECTIONSISSUER921342.0000000FOR921342.000000FORS000002106The Cooper Companies, Inc.216648501US216648501904/02/2025Approve an amendment to our Second Restated Certificate of Incorporation to provide for the exculpation of officers.CORPORATE GOVERNANCEISSUER921342.0000000FOR921342.000000FORS000002106The Cooper Companies, Inc.216648501US216648501904/02/2025Ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2025.AUDIT-RELATEDISSUER921342.0000000FOR921342.000000FORS000002106The Cooper Companies, Inc.216648501US216648501904/02/2025Approve, on a non-binding, advisory basis, the compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER921342.0000000FOR921342.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Election of Directors: Rodney ClarkDIRECTOR ELECTIONSISSUER2216255.0000000FOR2216255.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Election of Directors: James F. GentilcoreDIRECTOR ELECTIONSISSUER2216255.0000000FOR2216255.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Election of Directors: Yvette KanouffDIRECTOR ELECTIONSISSUER2216255.0000000FOR2216255.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Election of Directors: James P. LedererDIRECTOR ELECTIONSISSUER2216255.0000000FOR2216255.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Election of Directors: Bertrand LoyDIRECTOR ELECTIONSISSUER2216255.0000000FOR2216255.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Election of Directors: Mary PumaDIRECTOR ELECTIONSISSUER2216255.0000000FOR2216255.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Election of Directors: David ReederDIRECTOR ELECTIONSISSUER2216255.0000000FOR2216255.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Election of Directors: Azita Saleki-GerhardtDIRECTOR ELECTIONSISSUER2216255.0000000FOR2216255.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Approval, by non-binding vote, of the compensation paid to Entegris, Inc.'s named executive officers (advisory vote).SECTION 14A SAY-ON-PAY VOTESISSUER2216255.0000000FOR2216255.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Ratify the appointment of KPMG LLP as Entegris, Inc.'s Independent Registered Public Accounting Firm for 2025.AUDIT-RELATEDISSUER2216255.0000000FOR2216255.000000FORS000002106Entegris, Inc.29362U104US29362U104304/23/2025Stockholder Proposal Regarding Simple Majority Voting.CORPORATE GOVERNANCESECURITY HOLDER2216255.0000000AGAINST2216255.000000NONES000002106Teledyne Technologies Incorporated879360105US879360105004/23/2025Election of directors: Robert MehrabianDIRECTOR ELECTIONSISSUER1085814.0000000FOR1085814.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/23/2025Election of directors: Jane C. SherburneDIRECTOR ELECTIONSISSUER1085814.0000000FOR1085814.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/23/2025Election of directors: Michael T. SmithDIRECTOR ELECTIONSISSUER1085814.0000000FOR1085814.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/23/2025Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2025AUDIT-RELATEDISSUER1085814.0000000FOR1085814.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/23/2025Approval of a non-binding advisory resolution on the Company's 2024 executive compensation ("say on pay")SECTION 14A SAY-ON-PAY VOTESISSUER1085814.0000000FOR1085814.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/23/2025Approval of amendments to the Company's Restated Certificate of Incorporation to adopt majority voting provisionsCORPORATE GOVERNANCEISSUER1085814.0000000FOR1085814.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/23/2025Approval of a stockholder proposal to support shareholder ability to call for a special shareholder meetingCORPORATE GOVERNANCESECURITY HOLDER1085814.0000000AGAINST1085814.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Election of Directors: Di-Ann EisnorDIRECTOR ELECTIONSISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Election of Directors: Donna E. EppsDIRECTOR ELECTIONSISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Election of Directors: John P. Gainor, Jr.DIRECTOR ELECTIONSISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Election of Directors: Kevin A. HenryDIRECTOR ELECTIONSISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Election of Directors: Frederick J. Holzgrefe, IIIDIRECTOR ELECTIONSISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Election of Directors: Donald R. JamesDIRECTOR ELECTIONSISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Election of Directors: Randolph W. MehvilleDIRECTOR ELECTIONSISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Election of Directors: Richard D. O'DellDIRECTOR ELECTIONSISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Election of Directors: Jeffrey C. WardDIRECTOR ELECTIONSISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Election of Directors: Susan F. WardDIRECTOR ELECTIONSISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Approve on an advisory basis the compensation of Saia's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER1076840.0000000FOR1076840.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/24/2025Ratify the appointment of KPMG LLP as Saia's Independent Registered Public Accounting Firm for fiscal year 2025.AUDIT-RELATEDISSUER1076840.0000000FOR1076840.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2026 Annual General Meeting of Shareholders: Douglas J. PferdehirtDIRECTOR ELECTIONSISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2026 Annual General Meeting of Shareholders: Claire S. FarleyDIRECTOR ELECTIONSISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2026 Annual General Meeting of Shareholders: Eleazar de Carvalho FilhoDIRECTOR ELECTIONSISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2026 Annual General Meeting of Shareholders: Robert G. GwinDIRECTOR ELECTIONSISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2026 Annual General Meeting of Shareholders: John O'LearyDIRECTOR ELECTIONSISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2026 Annual General Meeting of Shareholders: Margareth OvrumDIRECTOR ELECTIONSISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2026 Annual General Meeting of Shareholders: Kay G. PriestlyDIRECTOR ELECTIONSISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2026 Annual General Meeting of Shareholders: John YearwoodDIRECTOR ELECTIONSISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2026 Annual General Meeting of Shareholders: Sophie ZurquiyahDIRECTOR ELECTIONSISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/20252024 U.S. Say-on-Pay for Named Executive Officers: To approve, as a non-binding advisory resolution, the Company's named executive officer compensation for the year ended December 31, 2024, as reported in the Company's Proxy StatementSECTION 14A SAY-ON-PAY VOTESISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Frequency of Future Say-on-Pay Proposals for Named Executive Officers: Approval of the frequency of future Say-on-Pay proposals for named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER7031553.0000000ONE YEAR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/20252024 U.K. Directors' Remuneration Report: To approve, as a non-binding advisory resolution, the Company's directors' remuneration report for the year ended December 31, 2024, as reported in the Company's U.K. Annual Report and AccountsCOMPENSATIONISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Prospective Directors' Remuneration Policy: To approve the Company's prospective directors' remuneration policy for the three years ending December 31, 2027, in the form presented in the Company's directors' remuneration report for the year ended December 31, 2024 of the Company's U.K. Annual Report and Accounts, such policy to take effect immediately after the conclusion of the 2025 Annual General Meeting of ShareholdersCOMPENSATIONISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Receipt of U.K. Annual Report and Accounts: To receive the Company's audited U.K. accounts for the year ended December 31, 2024, including the reports of the directors and the auditor thereonCORPORATE GOVERNANCEISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Ratification of PwC as U.S. Auditor: To ratify the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2025AUDIT-RELATEDISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Reappointment of PwC as U.K. Statutory Auditor: To reappoint PwC as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office from the conclusion of the 2025 Annual General Meeting of Shareholders until the next annual general meeting of shareholders at which accounts are laidAUDIT-RELATEDISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Approval of U.K. Statutory Auditor Fees: To authorize the Board and/or the Audit Committee to determine the remuneration of PwC, in its capacity as the Company's U.K. statutory auditor for the year ending December 31, 2025AUDIT-RELATEDISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025Authority to Allot Equity Securities: To authorize the Board to allot equity securities in the CompanyCAPITAL STRUCTUREISSUER7031553.0000000FOR7031553.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/25/2025As a special resolution - Authority to Allot Equity Securities without Pre-emptive Rights: Pursuant to the authority contemplated by the resolution in Proposal 10, to authorize the Board to allot equity securities without pre-emptive rightsCAPITAL STRUCTUREISSUER7031553.0000000FOR7031553.000000FORS000002106BeiGene Ltd.07725L102US07725L102604/28/2025THAT a special resolution that the deregistration of the Company in the Cayman Islands and the continuation of the Company to Switzerland be and hereby is approved and authorized (the "Continuation").EXTRAORDINARY TRANSACTIONSCORPORATE GOVERNANCEISSUER143046.0000000FOR143046.000000FORS000002106BeiGene Ltd.07725L102US07725L102604/28/2025Subject to, and effective only upon, (i) the approval of Resolution 1, (ii) the de-registration of the Company from the Register of Companies in the Cayman Islands and (iii) the simultaneous registration of the Continuation with the Swiss Commercial Register, THAT: 1. The seventh amended and restated memorandum and articles of association be amended and restated in the form set forth in Exhibit A to the proxy statement/prospectus (the "Proposed Swiss Articles") to be effective from the effective date of the Continuation. 2. The holders of ordinary shares represented in person or by proxy at the EGM hereby waive the option to discuss each individual article of the Proposed Swiss Articles and hereby approve the Proposed Swiss Articles in the form set forth in Exhibit A to the proxy statement/prospectus.CORPORATE GOVERNANCEISSUER143046.0000000FOR143046.000000FORS000002106BeiGene Ltd.07725L102US07725L102604/28/2025Subject to the approval of the Continuation and as required by Swiss law, THAT the election of Ernst & Young AG to serve as the Company's statutory auditor (for Swiss legal purposes) until the Company's first annual general meeting following the completion of the Continuation and provide the related audit services and the authorization to board of directors to fix the remuneration of Ernst & Young AG be and hereby is approved and authorized.AUDIT-RELATEDISSUER143046.0000000FOR143046.000000FORS000002106Globant SAL44385109LU097429987604/30/2025Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER1098804.0000000FOR1098804.000000FORS000002106Globant SAL44385109LU097429987604/30/2025Approve Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER1098804.0000000FOR1098804.000000FORS000002106Globant SAL44385109LU097429987604/30/2025Approve Allocation of IncomeCAPITAL STRUCTUREISSUER1098804.0000000FOR1098804.000000FORS000002106Globant SAL44385109LU097429987604/30/2025Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER1098804.0000000FOR1098804.000000FORS000002106Globant SAL44385109LU097429987604/30/2025Approve Remuneration of Directors during the Financial Year Ending on December 31, 2025COMPENSATIONISSUER1098804.0000000FOR1098804.000000FORS000002106Globant SAL44385109LU097429987604/30/2025Appoint PricewaterhouseCoopers, Societe Cooperative as Auditor for Annual Accounts and EU IFRS Consolidated AccountsAUDIT-RELATEDISSUER1098804.0000000FOR1098804.000000FORS000002106Globant SAL44385109LU097429987604/30/2025Appoint Price Waterhouse & Co. S.R.L. as Auditor for IFRS Consolidated AccountsAUDIT-RELATEDISSUER1098804.0000000FOR1098804.000000FORS000002106Globant SAL44385109LU097429987604/30/2025Reelect Maria Pinelli as DirectorDIRECTOR ELECTIONSISSUER1098804.0000000FOR1098804.000000FORS000002106Globant SAL44385109LU097429987604/30/2025Reelect Andrea Mayumi Petroni Merhy as DirectorDIRECTOR ELECTIONSISSUER1098804.0000000FOR1098804.000000FORS000002106Globant SAL44385109LU097429987604/30/2025Reelect Francisco Alvarez-Demalde as DirectorDIRECTOR ELECTIONSISSUER1098804.0000000FOR1098804.000000FORS000002106Bowhead Specialty Holdings Inc.10240L102US10240L102605/01/2025Election of Directors: Stephen SillsDIRECTOR ELECTIONSISSUER460962.0000000FOR460962.000000FORS000002106Bowhead Specialty Holdings Inc.10240L102US10240L102605/01/2025Election of Directors: Tom BakerDIRECTOR ELECTIONSISSUER460962.0000000FOR460962.000000FORS000002106Bowhead Specialty Holdings Inc.10240L102US10240L102605/01/2025Election of Directors: Matthew BoteinDIRECTOR ELECTIONSISSUER460962.0000000FOR460962.000000FORS000002106Bowhead Specialty Holdings Inc.10240L102US10240L102605/01/2025Election of Directors: Troy Van BeekDIRECTOR ELECTIONSISSUER460962.0000000FOR460962.000000FORS000002106Bowhead Specialty Holdings Inc.10240L102US10240L102605/01/2025Ratification of Pricewaterhouse Coopers LLP as Independent Registered Public Accounting Firm.AUDIT-RELATEDISSUER460962.0000000FOR460962.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Greg D. CarmichaelDIRECTOR ELECTIONSISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Edward M. Christie IIIDIRECTOR ELECTIONSISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Joan E. HermanDIRECTOR ELECTIONSISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Leslye G. KatzDIRECTOR ELECTIONSISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Patricia A. MarylandDIRECTOR ELECTIONSISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Kevin J. O'ConnorDIRECTOR ELECTIONSISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Christopher R. ReidyDIRECTOR ELECTIONSISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Nancy M. SchlichtingDIRECTOR ELECTIONSISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Mark J. TarrDIRECTOR ELECTIONSISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Terrance WilliamsDIRECTOR ELECTIONSISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025An advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER109469.0000000FOR109469.000000FORS000002106Encompass Health Corporation29261A100US29261A100705/01/2025A vote to approve the Company's 2025 Omnibus Performance Incentive Plan.COMPENSATIONISSUER109469.0000000FOR109469.000000FORS000002106Viper Energy, Inc.927959106US927959106205/01/2025Drop Down Proposal: To approve the acquisition by Viper Energy Partners LLC (the "Operating Company"), Viper's operating subsidiary, of all of the issued and outstanding equity interests of 1979 Royalties, LP and 1979 Royalties GP, LLC from Endeavor Energy Resources, LP, each of which is a subsidiary of Diamondback Energy, Inc., Viper's parent, pursuant to the equity purchase agreement by and among Viper, the Operating Company, Endeavor Energy Resources, LP, 1979 Royalties, LP and 1979 Royalties GP, LLC.EXTRAORDINARY TRANSACTIONSISSUER50633.0000000FOR50633.000000FORS000002106Viper Energy, Inc.927959106US927959106205/01/2025Equity Issuance Proposal: To approve, for the purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635, the issuance of an aggregate of (i) 69,626,640 units representing limited liability company interests in the Operating Company (the "Drop Down OpCo Units") and (ii) a number of shares of Viper's Class B Common Stock, par value $0.000001 per share, equal to the number of the Drop Down OpCo Units (the "Drop Down Class B Shares" and, together with the Drop Down OpCo Units, the "Equity Consideration"), in each case subject to the adjustments contemplated in, and otherwise subject to the terms and conditions of, the Drop Down Purchase Agreement, which Equity Consideration is exchangeable from time to time for an equal number of shares of Viper's Class A Common Stock, par value $0.000001 per share.EXTRAORDINARY TRANSACTIONSISSUER50633.0000000FOR50633.000000FORS000002106Viper Energy, Inc.927959106US927959106205/01/2025Adjournment Proposal: To adjourn the special meeting to a later date or time if necessary or appropriate, including to solicit additional proxies if there are not sufficient votes cast at the special meeting to approve the Drop Down Proposal and the Equity Issuance Proposal.CORPORATE GOVERNANCEISSUER50633.0000000AGAINST50633.000000AGAINSTS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To elect nine directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Brent BickettDIRECTOR ELECTIONSISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To elect nine directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Ronald ClarkeDIRECTOR ELECTIONSISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To elect nine directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Deborah FarringtonDIRECTOR ELECTIONSISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To elect nine directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Thomas HagertyDIRECTOR ELECTIONSISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To elect nine directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Linda MantiaDIRECTOR ELECTIONSISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To elect nine directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: David OssipDIRECTOR ELECTIONSISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To elect nine directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Ganesh RaoDIRECTOR ELECTIONSISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To elect nine directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Andrea RosenDIRECTOR ELECTIONSISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To elect nine directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Gerald ThroopDIRECTOR ELECTIONSISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To approve, on a non-binding, advisory basis, the compensation of Dayforce's named executive officers (commonly known as a "Say on Pay" vote)SECTION 14A SAY-ON-PAY VOTESISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To ratify the appointment of KPMG LLP as Dayforce's independent registered public accounting firm for the fiscal year ending December 31, 2025AUDIT-RELATEDISSUER9139774.0000000FOR9139774.000000FORS000002106Dayforce, Inc.15677J108US15677J108805/02/2025To approve Dayforce's Amended and Restated Certificate of IncorporationCORPORATE GOVERNANCEISSUER9139774.0000000FOR9139774.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025Election of Directors: Ford TamerDIRECTOR ELECTIONSISSUER2961148.0000000FOR2961148.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025Election of Directors: Robin AbramsDIRECTOR ELECTIONSISSUER2961148.0000000FOR2961148.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025Election of Directors: Douglas BettingerDIRECTOR ELECTIONSISSUER2961148.0000000FOR2961148.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025Election of Directors: Que Thanh DallaraDIRECTOR ELECTIONSISSUER2961148.0000000FOR2961148.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025Election of Directors: John ForsythDIRECTOR ELECTIONSISSUER2961148.0000000FOR2961148.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025Election of Directors: Mark JensenDIRECTOR ELECTIONSISSUER2961148.0000000FOR2961148.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025Election of Directors: James LedererDIRECTOR ELECTIONSISSUER2961148.0000000FOR2961148.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025Election of Directors: D. Jeffrey RichardsonDIRECTOR ELECTIONSISSUER2961148.0000000FOR2961148.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025Election of Directors: Elizabeth SchwartingDIRECTOR ELECTIONSISSUER2961148.0000000FOR2961148.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 3, 2026; andAUDIT-RELATEDISSUER2961148.0000000FOR2961148.000000FORS000002106Lattice Semiconductor Corporation518415104US518415104205/02/2025To approve on a non-binding, advisory basis, our Named Executive Officers' compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2961148.0000000FOR2961148.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025Election of Directors: Gerben W. BakkerDIRECTOR ELECTIONSISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025Election of Directors: Carlos M. CardosoDIRECTOR ELECTIONSISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025Election of Directors: Debra L. DialDIRECTOR ELECTIONSISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025Election of Directors: Anthony J. GuzziDIRECTOR ELECTIONSISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025Election of Directors: Rhett A. HernandezDIRECTOR ELECTIONSISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025Election of Directors: Neal J. KeatingDIRECTOR ELECTIONSISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025Election of Directors: Bonnie C. LindDIRECTOR ELECTIONSISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025Election of Directors: John F. MalloyDIRECTOR ELECTIONSISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025Election of Directors: Jennifer M. PollinoDIRECTOR ELECTIONSISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025Election of Directors: Garrick J. RochowDIRECTOR ELECTIONSISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025To approve, by advisory vote, the compensation of our Named Executive Officers as presented in the 2025 Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year 2025.AUDIT-RELATEDISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025To approve the amendment and restatement to the Certificate of Incorporation to adopt a majority voting standard in uncontested elections of Directors.CORPORATE GOVERNANCEISSUER441736.0000000FOR441736.000000FORS000002106Hubbell Incorporated443510607US443510607905/06/2025To approve the Hubbell Incorporated Incentive Award Plan.COMPENSATIONISSUER441736.0000000FOR441736.000000FORS000002106Trex Company, Inc.89531P105US89531P105705/06/2025Election of Directors: Bryan H. FairbanksDIRECTOR ELECTIONSISSUER2781413.0000000FOR2781413.000000FORS000002106Trex Company, Inc.89531P105US89531P105705/06/2025Election of Directors: Kristine L. JusterDIRECTOR ELECTIONSISSUER2781413.0000000AGAINST2781413.000000AGAINSTS000002106Trex Company, Inc.89531P105US89531P105705/06/2025Election of Directors: D. Christian KefferDIRECTOR ELECTIONSISSUER2781413.0000000FOR2781413.000000FORS000002106Trex Company, Inc.89531P105US89531P105705/06/2025Non-binding advisory vote on executive compensation ("say-on-pay")SECTION 14A SAY-ON-PAY VOTESISSUER2781413.0000000FOR2781413.000000FORS000002106Trex Company, Inc.89531P105US89531P105705/06/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2025 fiscal yearAUDIT-RELATEDISSUER2781413.0000000FOR2781413.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: Nada AriedDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: Norman AxelrodDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: William GilesDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: Dwight JamesDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: Melissa KerseyDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: Ryan MarshallDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: Richard SullivanDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: Thomas TaylorDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: Felicia ThortonDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: George Vincent WestDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Election of Directors: Charles YoungDIRECTOR ELECTIONSISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Ratify the appointment of Ernst & Young LLP as independent auditors for Floor & Decor Holdings, Inc.'s (the "Company") 2025 fiscal year.AUDIT-RELATEDISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Approve, by non-binding vote, the compensation paid to the Company's named executive officers for the 2024 fiscal year.SECTION 14A SAY-ON-PAY VOTESISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Approve an amendment to the Company's Certificate of Incorporation to eliminate legacy classified board provisions that no longer apply.CORPORATE GOVERNANCEISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Approve an amendment to the Company's Certificate of Incorporation to provide for exculpation of officers as permitted by Delaware law.CORPORATE GOVERNANCEISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Approve an amendment to the Company's Certificate of Incorporation to allow stockholders holding 25% or more of the Company's common stock to cause the Company to call a special meeting of stockholders.CORPORATE GOVERNANCEISSUER2555066.0000000FOR2555066.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/07/2025Stockholder proposal regarding shareholder ability to call for a special shareholder meeting.CORPORATE GOVERNANCESECURITY HOLDER2555066.0000000AGAINST2555066.000000FORS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To elect the following nominees as Class III directors of Alnylam: Carolyn R. Bertozzi, Ph.D.DIRECTOR ELECTIONSISSUER984375.0000000AGAINST984375.000000AGAINSTS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To elect the following nominees as Class III directors of Alnylam: Margaret A. Hamburg, M.D.DIRECTOR ELECTIONSISSUER984375.0000000AGAINST984375.000000AGAINSTS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To elect the following nominees as Class III directors of Alnylam: Colleen F. ReitanDIRECTOR ELECTIONSISSUER984375.0000000AGAINST984375.000000AGAINSTS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To elect the following nominees as Class III directors of Alnylam: Amy W. SchulmanDIRECTOR ELECTIONSISSUER984375.0000000AGAINST984375.000000AGAINSTS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To approve an Amendment to our Restated Certificate of Incorporation allowing for officer exculpation.CORPORATE GOVERNANCEISSUER984375.0000000FOR984375.000000FORS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To approve the second amended and restated 2018 Stock Incentive Plan.COMPENSATIONISSUER984375.0000000FOR984375.000000FORS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER984375.0000000FOR984375.000000FORS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER984375.0000000FOR984375.000000FORS000002106ESAB Corporation29605J106US29605J106005/08/2025Election of Directors: Melissa CummingsDIRECTOR ELECTIONSISSUER3112979.0000000FOR3112979.000000FORS000002106ESAB Corporation29605J106US29605J106005/08/2025Election of Directors: Shyam P. KambeyandaDIRECTOR ELECTIONSISSUER3112979.0000000FOR3112979.000000FORS000002106ESAB Corporation29605J106US29605J106005/08/2025Election of Directors: Robert S. LutzDIRECTOR ELECTIONSISSUER3112979.0000000FOR3112979.000000FORS000002106ESAB Corporation29605J106US29605J106005/08/2025Election of Directors: Rajiv VinnakotaDIRECTOR ELECTIONSISSUER3112979.0000000FOR3112979.000000FORS000002106ESAB Corporation29605J106US29605J106005/08/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER3112979.0000000FOR3112979.000000FORS000002106ESAB Corporation29605J106US29605J106005/08/2025To approve on an advisory basis the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3112979.0000000FOR3112979.000000FORS000002106ESAB Corporation29605J106US29605J106005/08/2025To approve the Amended and Restated ESAB Corporation 2022 Omnibus Incentive Plan.COMPENSATIONISSUER3112979.0000000FOR3112979.000000FORS000002106IDEX Corporation45167R104US45167R104105/08/2025Election of three directors named in the proxy statement as follows: Class III Nominees (each for a term of three years): Eric D. AshlemanDIRECTOR ELECTIONSISSUER1312799.0000000FOR1312799.000000FORS000002106IDEX Corporation45167R104US45167R104105/08/2025Election of three directors named in the proxy statement as follows: Class III Nominees (each for a term of three years): Stephanie J. DisherDIRECTOR ELECTIONSISSUER1312799.0000000FOR1312799.000000FORS000002106IDEX Corporation45167R104US45167R104105/08/2025Election of three directors named in the proxy statement as follows: Class III Nominees (each for a term of three years): Matthijs GlastraDIRECTOR ELECTIONSISSUER1312799.0000000FOR1312799.000000FORS000002106IDEX Corporation45167R104US45167R104105/08/2025Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1312799.0000000FOR1312799.000000FORS000002106IDEX Corporation45167R104US45167R104105/08/2025Ratification of the appointment of Deloitte & Touche LLP as our independent registered accounting firm for 2025.AUDIT-RELATEDISSUER1312799.0000000FOR1312799.000000FORS000002106IDEX Corporation45167R104US45167R104105/08/2025Vote on a stockholder proposal regarding a report on hiring practices related to people with arrest or incarceration records.HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCEDIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER1312799.0000000AGAINST1312799.000000FORS000002106MSA Safety Incorporated553498106US553498106405/13/2025Election of Directors for a term expiring in 2028: Robert A. BruggeworthDIRECTOR ELECTIONSISSUER634244.0000000WITHHOLD634244.000000AGAINSTS000002106MSA Safety Incorporated553498106US553498106405/13/2025Election of Directors for a term expiring in 2028: Gregory B. JordanDIRECTOR ELECTIONSISSUER634244.0000000WITHHOLD634244.000000AGAINSTS000002106MSA Safety Incorporated553498106US553498106405/13/2025Election of Directors for a term expiring in 2028: William R. SperryDIRECTOR ELECTIONSISSUER634244.0000000WITHHOLD634244.000000AGAINSTS000002106MSA Safety Incorporated553498106US553498106405/13/2025Selection of Ernst & Young LLP as the Company's independent registered public accounting firm.AUDIT-RELATEDISSUER634244.0000000FOR634244.000000FORS000002106MSA Safety Incorporated553498106US553498106405/13/2025To provide an advisory vote to approve the executive compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER634244.0000000FOR634244.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To elect, by separate resolution, three directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2028, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Paula K. CobbDIRECTOR ELECTIONSISSUER1889455.0000000FOR1889455.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To elect, by separate resolution, three directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2028, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Lars G. EkmanDIRECTOR ELECTIONSISSUER1889455.0000000FOR1889455.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To elect, by separate resolution, three directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2028, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Gene G. KinneyDIRECTOR ELECTIONSISSUER1889455.0000000FOR1889455.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To ratify, on a non-binding vote, the appointment of KPMG LLP as the Company's independent registered public accounting firm for its fiscal year 2025, and to authorize, in a binding vote, the Company's Board of Directors, acting through its Audit Committee, to approve remuneration of that auditor.AUDIT-RELATEDISSUER1889455.0000000FOR1889455.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To approve, in a non-binding advisory vote, the compensation of the executive officers named in the Company's Proxy Statement for the Annual General Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER1889455.0000000FOR1889455.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To approve an amendment to the Company's 2018 Long Term Incentive Plan to increase the number of ordinary shares available for issuance under that Plan by 2,000,000 ordinary shares.COMPENSATIONISSUER1889455.0000000FOR1889455.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/14/2025To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: John T. HendersonDIRECTOR ELECTIONSISSUER596715.0000000FOR596715.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/14/2025To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: B. Lynne ParshallDIRECTOR ELECTIONSISSUER596715.0000000FOR596715.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/14/2025To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: Muna BhanjiDIRECTOR ELECTIONSISSUER596715.0000000FOR596715.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/14/2025To approve the amendment and restatement of the Cytokinetics Amended and Restated 2004 Equity Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under such plan by 5,000,000 shares of common stock and (ii) provide for limitations on the maximum grant value that non-executive directors may receive under such plan of $1,000,000 for annual grants to continuing directors and $1,250,000 for the initial grant to new directors.COMPENSATIONISSUER596715.0000000FOR596715.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/14/2025To approve an amendment to Cytokinetics, Incorporated's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common available for issuance by Cytokinetics, Incorporated from 163,000,000 to 326,000,000 shares of common stock.CAPITAL STRUCTUREISSUER596715.0000000FOR596715.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/14/2025To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Cytokinetics, Incorporated's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER596715.0000000FOR596715.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/14/2025To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER596715.0000000FOR596715.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/14/2025Election of Directors: Fred M. DiazDIRECTOR ELECTIONSISSUER3000462.0000000FOR3000462.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/14/2025Election of Directors: W. Roy DunbarDIRECTOR ELECTIONSISSUER3000462.0000000FOR3000462.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/14/2025Election of Directors: Larisa J. DrakeDIRECTOR ELECTIONSISSUER3000462.0000000FOR3000462.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/14/2025Approval of an amendment to the company's Charter to declassify our board of directors.SHAREHOLDER RIGHTS AND DEFENSESISSUER3000462.0000000FOR3000462.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/14/2025Ratification of the selection of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 28, 2025.AUDIT-RELATEDISSUER3000462.0000000FOR3000462.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/14/2025Advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER3000462.0000000FOR3000462.000000FORS000002106SpringWorks Therapeutics, Inc.85205L107US85205L107005/14/2025Election of Class III Directors: Alan FuhrmanDIRECTOR ELECTIONSISSUER964892.0000000FOR964892.000000FORS000002106SpringWorks Therapeutics, Inc.85205L107US85205L107005/14/2025Election of Class III Directors: Julie Hambleton, M.D.DIRECTOR ELECTIONSISSUER964892.0000000FOR964892.000000FORS000002106SpringWorks Therapeutics, Inc.85205L107US85205L107005/14/2025Election of Class III Directors: Daniel S. Lynch, M.B.A.DIRECTOR ELECTIONSISSUER964892.0000000FOR964892.000000FORS000002106SpringWorks Therapeutics, Inc.85205L107US85205L107005/14/2025Ratification of the appointment of Ernst & Young LLP as SpringWorks Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2025AUDIT-RELATEDISSUER964892.0000000FOR964892.000000FORS000002106SpringWorks Therapeutics, Inc.85205L107US85205L107005/14/2025Non-binding advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER964892.0000000FOR964892.000000FORS000002106Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of stockholders: Marshall Fordyce, M.D.DIRECTOR ELECTIONSISSUER1700854.0000000FOR1700854.000000FORS000002106Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of stockholders: Beth Seidenberg, M.D.DIRECTOR ELECTIONSISSUER1700854.0000000FOR1700854.000000FORS000002106Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of stockholders: Kimball HallDIRECTOR ELECTIONSISSUER1700854.0000000FOR1700854.000000FORS000002106Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1700854.0000000FOR1700854.000000FORS000002106Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1700854.0000000FOR1700854.000000FORS000002106Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1700854.0000000ONE YEAR1700854.000000FORS000002106Insmed Incorporated457669307US457669307505/15/2025Election of two Class I directors, Leo Lee and William H. Lewis, to serve until the 2028 Annual Meeting of Shareholders: Leo LeeDIRECTOR ELECTIONSISSUER4674824.0000000WITHHOLD4674824.000000AGAINSTS000002106Insmed Incorporated457669307US457669307505/15/2025Election of two Class I directors, Leo Lee and William H. Lewis, to serve until the 2028 Annual Meeting of Shareholders: William H. LewisDIRECTOR ELECTIONSISSUER4674824.0000000FOR4674824.000000FORS000002106Insmed Incorporated457669307US457669307505/15/2025An advisory vote on the 2024 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4674824.0000000FOR4674824.000000FORS000002106Insmed Incorporated457669307US457669307505/15/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER4674824.0000000FOR4674824.000000FORS000002106Insmed Incorporated457669307US457669307505/15/2025Approval of Amendment No. 2 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.COMPENSATIONISSUER4674824.0000000FOR4674824.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Election of Directors: Olivier LoeillotDIRECTOR ELECTIONSISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Election of Directors: Tony J. HuntDIRECTOR ELECTIONSISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Election of Directors: Karen A. DawesDIRECTOR ELECTIONSISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Election of Directors: Nicolas M. BarthelemyDIRECTOR ELECTIONSISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Election of Directors: Carrie Eglinton MannerDIRECTOR ELECTIONSISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Election of Directors: Konstantin Konstantinov, Ph.D.DIRECTOR ELECTIONSISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Election of Directors: Martin D. Madaus, D.V.M., Ph.D.DIRECTOR ELECTIONSISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Election of Directors: Rohin Mhatre, Ph.D.DIRECTOR ELECTIONSISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Election of Directors: Glenn P. MuirDIRECTOR ELECTIONSISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Election of Directors: Margaret A. PaxDIRECTOR ELECTIONSISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Ratification of the selection of Ernst & Young LLP as Repligen Corporation's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Advisory vote to approve the compensation paid to Repligen Corporation's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1315334.0000000FOR1315334.000000FORS000002106Repligen Corporation759916109US759916109505/15/2025Approval of an amendment to the Corporation's certificate of incorporation to limit the liability of certain officers of the company as permitted by Delaware law.CORPORATE GOVERNANCEISSUER1315334.0000000FOR1315334.000000FORS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/15/2025Nominees: Matthew K. FustDIRECTOR ELECTIONSISSUER783990.0000000FOR783990.000000FORS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/15/2025Nominees: Amrit Ray, M.D.DIRECTOR ELECTIONSISSUER783990.0000000FOR783990.000000FORS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/15/2025Approval of the Second Amended and Restated 2023 Incentive Plan.COMPENSATIONISSUER783990.0000000FOR783990.000000FORS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/15/2025Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER783990.0000000FOR783990.000000FORS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/15/2025Advisory (non-binding) vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER783990.0000000FOR783990.000000FORS000002106Viking Holdings LtdG93A5A101BMG93A5A101005/15/2025Elect Director Torstein HagenDIRECTOR ELECTIONSISSUER745198.0000000AGAINST745198.000000AGAINSTS000002106Viking Holdings LtdG93A5A101BMG93A5A101005/15/2025Elect Director Richard FearDIRECTOR ELECTIONSISSUER745198.0000000FOR745198.000000FORS000002106Viking Holdings LtdG93A5A101BMG93A5A101005/15/2025Elect Director Morten GarmanDIRECTOR ELECTIONSISSUER745198.0000000FOR745198.000000FORS000002106Viking Holdings LtdG93A5A101BMG93A5A101005/15/2025Elect Director Paul HackwellDIRECTOR ELECTIONSISSUER745198.0000000FOR745198.000000FORS000002106Viking Holdings LtdG93A5A101BMG93A5A101005/15/2025Elect Director Karine HagenDIRECTOR ELECTIONSISSUER745198.0000000FOR745198.000000FORS000002106Viking Holdings LtdG93A5A101BMG93A5A101005/15/2025Elect Director Tore MyrholtDIRECTOR ELECTIONSISSUER745198.0000000FOR745198.000000FORS000002106Viking Holdings LtdG93A5A101BMG93A5A101005/15/2025Elect Director Pat NaccaratoDIRECTOR ELECTIONSISSUER745198.0000000FOR745198.000000FORS000002106Viking Holdings LtdG93A5A101BMG93A5A101005/15/2025Elect Director Jack WeingartDIRECTOR ELECTIONSISSUER745198.0000000FOR745198.000000FORS000002106Viking Holdings LtdG93A5A101BMG93A5A101005/15/2025Elect Torstein Hagen as Board ChairmanDIRECTOR ELECTIONSISSUER745198.0000000AGAINST745198.000000AGAINSTS000002106Viking Holdings LtdG93A5A101BMG93A5A101005/15/2025Approve Ernst & Young AS as Auditors and Authorize Board to Fix Their RemunerationAUDIT-RELATEDISSUER745198.0000000FOR745198.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To elect nine directors for a one-year term expiring at the 2026 Annual Meeting of Shareholders: Sir Martin E. FranklinDIRECTOR ELECTIONSISSUER3815214.0000000FOR3815214.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To elect nine directors for a one-year term expiring at the 2026 Annual Meeting of Shareholders: James E. LillieDIRECTOR ELECTIONSISSUER3815214.0000000FOR3815214.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To elect nine directors for a one-year term expiring at the 2026 Annual Meeting of Shareholders: Ian G.H. AshkenDIRECTOR ELECTIONSISSUER3815214.0000000FOR3815214.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To elect nine directors for a one-year term expiring at the 2026 Annual Meeting of Shareholders: Russell A. BeckerDIRECTOR ELECTIONSISSUER3815214.0000000FOR3815214.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To elect nine directors for a one-year term expiring at the 2026 Annual Meeting of Shareholders: Paula D. LoopDIRECTOR ELECTIONSISSUER3815214.0000000FOR3815214.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To elect nine directors for a one-year term expiring at the 2026 Annual Meeting of Shareholders: Anthony E. MalkinDIRECTOR ELECTIONSISSUER3815214.0000000FOR3815214.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To elect nine directors for a one-year term expiring at the 2026 Annual Meeting of Shareholders: Thomas V. MilroyDIRECTOR ELECTIONSISSUER3815214.0000000FOR3815214.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To elect nine directors for a one-year term expiring at the 2026 Annual Meeting of Shareholders: Cyrus D. WalkerDIRECTOR ELECTIONSISSUER3815214.0000000FOR3815214.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To elect nine directors for a one-year term expiring at the 2026 Annual Meeting of Shareholders: Carrie A. WheelerDIRECTOR ELECTIONSISSUER3815214.0000000AGAINST3815214.000000AGAINSTS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the 2025 fiscal year.AUDIT-RELATEDISSUER3815214.0000000FOR3815214.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3815214.0000000FOR3815214.000000FORS000002106APi Group Corporation00187Y100US00187Y100105/16/2025To approve the amendment of our certificate of incorporation to increase the number of authorized shares of common stock.CAPITAL STRUCTUREISSUER3815214.0000000FOR3815214.000000FORS000002106Nurix Therapeutics, Inc.67080M103US67080M103605/19/2025Election of Directors: Judith A. ReinsdorfDIRECTOR ELECTIONSISSUER1333790.0000000FOR1333790.000000FORS000002106Nurix Therapeutics, Inc.67080M103US67080M103605/19/2025Election of Directors: Edward C. SaltzmanDIRECTOR ELECTIONSISSUER1333790.0000000FOR1333790.000000FORS000002106Nurix Therapeutics, Inc.67080M103US67080M103605/19/2025Election of Directors: Roy D. BaynesDIRECTOR ELECTIONSISSUER1333790.0000000FOR1333790.000000FORS000002106Nurix Therapeutics, Inc.67080M103US67080M103605/19/2025Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2025.AUDIT-RELATEDISSUER1333790.0000000FOR1333790.000000FORS000002106Nurix Therapeutics, Inc.67080M103US67080M103605/19/2025To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1333790.0000000FOR1333790.000000FORS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT Mr. Anthony C. Hooper be and is hereby re-elected to serve as a Class III director of the Company until the 2028 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER133344.0000000FOR133344.000000FORS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT Mr. Ranjeev Krishana be and is hereby re-elected to serve as a Class III director of the Company until the 2028 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER133344.0000000FOR133344.000000FORS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT Dr. Xiaodong Wang be and is hereby re-elected to serve as a Class III director of the Company until the 2028 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER133344.0000000FOR133344.000000FORS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT Mr. Qingqing Yi be and is hereby re-elected to serve as a Class III director of the Company until the 2028 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER133344.0000000FOR133344.000000FORS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT Ms. Shalini Sharp be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal.DIRECTOR ELECTIONSISSUER133344.0000000AGAINST133344.000000AGAINSTS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2025 be and is hereby ratified and confirmed.AUDIT-RELATEDISSUER133344.0000000FOR133344.000000FORS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT the Board of Directors is hereby authorized to fix the auditors' compensation for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER133344.0000000FOR133344.000000FORS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares ("ADSs") (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of this ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.CAPITAL STRUCTUREISSUER133344.0000000AGAINST133344.000000AGAINSTS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding the Company's ordinary shares listed on the Science and Technology Innovation Board of Shanghai Stock Exchange and traded in RMB ("RMB shares")) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of this ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.CAPITAL STRUCTUREISSUER133344.0000000FOR133344.000000FORS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 8 for a period of five years, which period will be subject to an extension on a rolling basis each year.CAPITAL STRUCTUREISSUER133344.0000000AGAINST133344.000000AGAINSTS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER133344.0000000AGAINST133344.000000AGAINSTS000002106BeiGene Ltd.07725L102US07725L102605/21/2025THAT the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of the proposals described above, be and is hereby approved.CORPORATE GOVERNANCEISSUER133344.0000000AGAINST133344.000000AGAINSTS000002106Merus N.V.N5749R100NL001160626405/21/2025Adoption of Merus N.V.'s Dutch statutory annual accounts for the financial year 2024.CORPORATE GOVERNANCEISSUER378438.0000000FOR378438.000000FORS000002106Merus N.V.N5749R100NL001160626405/21/2025Appointment of KPMG Accountants N.V. as Merus N.V.'s external auditor for the financial year 2025 for purposes of Dutch law.AUDIT-RELATEDISSUER378438.0000000FOR378438.000000FORS000002106Merus N.V.N5749R100NL001160626405/21/2025Release of each member of Merus N.V.'s board of directors from liability for the exercise of their duties during the financial year 2024.CORPORATE GOVERNANCEISSUER378438.0000000FOR378438.000000FORS000002106Merus N.V.N5749R100NL001160626405/21/2025Opportunity to make recommendations for nomination by Merus N.V.'s group of non-executive directors.CORPORATE GOVERNANCEISSUER378438.0000000FOR378438.000000FORS000002106Merus N.V.N5749R100NL001160626405/21/2025Re-appointment of Anand Mehra, M.D. as non-executive director.DIRECTOR ELECTIONSISSUER378438.0000000FOR378438.000000FORS000002106Merus N.V.N5749R100NL001160626405/21/2025Opportunity to make recommendations for nomination by Merus N.V.'s group of non-executive directors.CORPORATE GOVERNANCEISSUER378438.0000000FOR378438.000000FORS000002106Merus N.V.N5749R100NL001160626405/21/2025Re-appointment of Maxine Gowen, Ph.D. as non-executive director.DIRECTOR ELECTIONSISSUER378438.0000000FOR378438.000000FORS000002106Merus N.V.N5749R100NL001160626405/21/2025Granting authorization to Merus N.V.'s board of directors to acquire shares (or depository receipts for such shares) in Merus N.V.'s capital.CAPITAL STRUCTUREISSUER378438.0000000FOR378438.000000FORS000002106Merus N.V.N5749R100NL001160626405/21/2025Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER378438.0000000FOR378438.000000FORS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Kyle W. Gano, Ph.D.DIRECTOR ELECTIONSISSUER200479.0000000FOR200479.000000FORS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Richard F. PopsDIRECTOR ELECTIONSISSUER200479.0000000WITHHOLD200479.000000AGAINSTS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Shalini SharpDIRECTOR ELECTIONSISSUER200479.0000000WITHHOLD200479.000000AGAINSTS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Stephen A. Sherwin, M.D.DIRECTOR ELECTIONSISSUER200479.0000000WITHHOLD200479.000000AGAINSTS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025Advisory vote on the compensation paid to the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER200479.0000000FOR200479.000000FORS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025To approve the Company's 2025 Equity Incentive Plan;COMPENSATIONISSUER200479.0000000FOR200479.000000FORS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025To approve an amendment and restatement of the Company's 2018 Employee Stock Purchase Plan; andCOMPENSATIONISSUER200479.0000000FOR200479.000000FORS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER200479.0000000FOR200479.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Sherry A. AaholmDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: David S. CongdonDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: John R. Congdon, Jr.DIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Andrew S. DavisDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Kevin M. FreemanDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Bradley R. GaboschDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Greg C. GanttDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: John D. KasardaDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Debra S. KingDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Cheryl S. MillerDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Wendy T. StallingsDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Thomas A. Stith, IIIDIRECTOR ELECTIONSISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Approval of the Old Dominion Freight Line, Inc. 2025 Stock Incentive Plan.COMPENSATIONISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER2295396.0000000FOR2295396.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/21/2025Shareholder proposal regarding emission reduction targets.ENVIRONMENT OR CLIMATESECURITY HOLDER2295396.0000000AGAINST2295396.000000FORS000002106Reliance, Inc.759509102US759509102305/21/2025Election of Directors: Lisa L. BaldwinDIRECTOR ELECTIONSISSUER1049770.0000000FOR1049770.000000FORS000002106Reliance, Inc.759509102US759509102305/21/2025Election of Directors: Karen W. ColoniasDIRECTOR ELECTIONSISSUER1049770.0000000FOR1049770.000000FORS000002106Reliance, Inc.759509102US759509102305/21/2025Election of Directors: Frank J. DellaquilaDIRECTOR ELECTIONSISSUER1049770.0000000FOR1049770.000000FORS000002106Reliance, Inc.759509102US759509102305/21/2025Election of Directors: James K. KamsickasDIRECTOR ELECTIONSISSUER1049770.0000000FOR1049770.000000FORS000002106Reliance, Inc.759509102US759509102305/21/2025Election of Directors: Karla R. LewisDIRECTOR ELECTIONSISSUER1049770.0000000FOR1049770.000000FORS000002106Reliance, Inc.759509102US759509102305/21/2025Election of Directors: Robert A. McEvoyDIRECTOR ELECTIONSISSUER1049770.0000000FOR1049770.000000FORS000002106Reliance, Inc.759509102US759509102305/21/2025Election of Directors: David W. SeegerDIRECTOR ELECTIONSISSUER1049770.0000000FOR1049770.000000FORS000002106Reliance, Inc.759509102US759509102305/21/2025Election of Directors: Douglas W. StotlarDIRECTOR ELECTIONSISSUER1049770.0000000FOR1049770.000000FORS000002106Reliance, Inc.759509102US759509102305/21/2025To consider a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1049770.0000000FOR1049770.000000FORS000002106Reliance, Inc.759509102US759509102305/21/2025To ratify the appointment of KPMG LLP as our independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER1049770.0000000FOR1049770.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Approve Allocation of Income and Omission of DividendsCAPITAL STRUCTUREISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Approve Non-Financial ReportCORPORATE GOVERNANCEENVIRONMENT OR CLIMATEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Approve Discharge of Board and Senior ManagementCORPORATE GOVERNANCEISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reelect Alex Perez as Representative of Class A Shares HoldersDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reelect David Allemann as DirectorDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reelect Amy Banse as DirectorDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reelect Olivier Bernhard as DirectorDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reelect Caspar Coppetti as DirectorDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reelect Dennis Durkin as DirectorDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reelect Laura Miele as DirectorDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reelect Alex Perez as DirectorDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Elect Helena Helmersson as DirectorDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reelect David Allemann as Board Co-ChairDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reelect Caspar Coppetti as Board Co-ChairDIRECTOR ELECTIONSISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reappoint Amy Banse as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Appoint Helena Helmersson as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Reappoint Alex Perez as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Designate Keller AG as Independent ProxyCORPORATE GOVERNANCEISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Ratify PricewaterhouseCoopers AG as AuditorsAUDIT-RELATEDISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Approve Remuneration Report (Non-Binding)COMPENSATIONISSUER952513.0000000AGAINST952513.000000AGAINSTS000002106On Holding AGH5919C104CH113454047005/22/2025Approve Remuneration of Directors in the Amount of CHF 2 MillionCOMPENSATIONISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Approve Remuneration of Executive Committee in the Amount of CHF 30 MillionCOMPENSATIONISSUER952513.0000000AGAINST952513.000000AGAINSTS000002106On Holding AGH5919C104CH113454047005/22/2025Approve Conversion of Class B Shares into Class A SharesCAPITAL STRUCTUREISSUER952513.0000000FOR952513.000000FORS000002106On Holding AGH5919C104CH113454047005/22/2025Transact Other Business (Voting)CORPORATE GOVERNANCEISSUER952513.0000000AGAINST952513.000000AGAINSTS000002106SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103005/22/2025To elect three Class I directors to our Board of Directors, each to serve until the 2028 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Srinivas Akkaraju, M.D., Ph.D.DIRECTOR ELECTIONSISSUER3819986.0000000FOR3819986.000000FORS000002106SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103005/22/2025To elect three Class I directors to our Board of Directors, each to serve until the 2028 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Joshua ReedDIRECTOR ELECTIONSISSUER3819986.0000000FOR3819986.000000FORS000002106SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103005/22/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3819986.0000000FOR3819986.000000FORS000002106Wingstop Inc.974155103US974155103305/22/2025Elect four Class I directors nominated by the Board of Directors for a term that expires at the 2028 Annual Meeting of Stockholders: Krishnan (Kandy) AnandDIRECTOR ELECTIONSISSUER757395.0000000FOR757395.000000FORS000002106Wingstop Inc.974155103US974155103305/22/2025Elect four Class I directors nominated by the Board of Directors for a term that expires at the 2028 Annual Meeting of Stockholders: David L. GoebelDIRECTOR ELECTIONSISSUER757395.0000000FOR757395.000000FORS000002106Wingstop Inc.974155103US974155103305/22/2025Elect four Class I directors nominated by the Board of Directors for a term that expires at the 2028 Annual Meeting of Stockholders: Thomas R. GrecoDIRECTOR ELECTIONSISSUER757395.0000000FOR757395.000000FORS000002106Wingstop Inc.974155103US974155103305/22/2025Elect four Class I directors nominated by the Board of Directors for a term that expires at the 2028 Annual Meeting of Stockholders: Michael J. HislopDIRECTOR ELECTIONSISSUER757395.0000000FOR757395.000000FORS000002106Wingstop Inc.974155103US974155103305/22/2025Ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for fiscal year 2025.AUDIT-RELATEDISSUER757395.0000000FOR757395.000000FORS000002106Wingstop Inc.974155103US974155103305/22/2025Approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER757395.0000000FOR757395.000000FORS000002106Wingstop Inc.974155103US974155103305/22/2025Approve an amendment to the Wingstop Inc. Certificate of Incorporation to declassify the Board of Directors.SHAREHOLDER RIGHTS AND DEFENSESISSUER757395.0000000FOR757395.000000FORS000002106Wingstop Inc.974155103US974155103305/22/2025Approve an amendment to the Wingstop Inc. Certificate of Incorporation to eliminate supermajority voting provisions.CORPORATE GOVERNANCEISSUER757395.0000000FOR757395.000000FORS000002106argenx SE04016X101US04016X101905/27/2025Approve Remuneration ReportCOMPENSATIONISSUER700352.0000000FOR700352.000000FORS000002106argenx SE04016X101US04016X101905/27/2025Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER700352.0000000FOR700352.000000FORS000002106argenx SE04016X101US04016X101905/27/2025Approve Allocation of Income to the Retained Earnings of the CompanyCAPITAL STRUCTUREISSUER700352.0000000FOR700352.000000FORS000002106argenx SE04016X101US04016X101905/27/2025Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER700352.0000000FOR700352.000000FORS000002106argenx SE04016X101US04016X101905/27/2025Approve Remuneration PolicyCOMPENSATIONISSUER700352.0000000FOR700352.000000FORS000002106argenx SE04016X101US04016X101905/27/2025Reelect Anthony Rosenberg as Non-Executive DirectorDIRECTOR ELECTIONSISSUER700352.0000000FOR700352.000000FORS000002106argenx SE04016X101US04016X101905/27/2025Grant Board Authority to Issue Shares and Exclude Pre-emptive RightsCAPITAL STRUCTUREISSUER700352.0000000FOR700352.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Elect Lars Luthjohan as Chair of MeetingCORPORATE GOVERNANCEISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Accept Financial Statements and Statutory Reports; Approve Discharge of Management and BoardCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Approve Treatment of Net LossCAPITAL STRUCTUREISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect Albert Cha as DirectorDIRECTOR ELECTIONSISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect Lars Holtug as DirectorDIRECTOR ELECTIONSISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect Jan Moller Mikkelsen as DirectorDIRECTOR ELECTIONSISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect Lisa Jane Morrison as DirectorDIRECTOR ELECTIONSISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect William Carl Fairey Jr as DirectorDIRECTOR ELECTIONSISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect Siham Imani as DirectorDIRECTOR ELECTIONSISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Ratify Deloitte as AuditorAUDIT-RELATEDISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Approve Creation of DKK 3.8 Million Pool of Capital without Preemptive RightsCAPITAL STRUCTUREISSUER576332.0000000FOR576332.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Approve Issuance of Warrants to Board MembersCOMPENSATIONISSUER576332.0000000AGAINST576332.000000AGAINSTS000002106Ascendis Pharma A/S04351P101US04351P101205/27/2025Amend Articles Re: Board-RelatedCORPORATE GOVERNANCEISSUER576332.0000000FOR576332.000000FORS000002106Arcellx, Inc.03940C100US03940C100905/28/2025To elect three Class III directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified: Rami ElghandourDIRECTOR ELECTIONSISSUER433731.0000000FOR433731.000000FORS000002106Arcellx, Inc.03940C100US03940C100905/28/2025To elect three Class III directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified: David LubnerDIRECTOR ELECTIONSISSUER433731.0000000FOR433731.000000FORS000002106Arcellx, Inc.03940C100US03940C100905/28/2025To elect three Class III directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified: Kristin MyersDIRECTOR ELECTIONSISSUER433731.0000000FOR433731.000000FORS000002106Arcellx, Inc.03940C100US03940C100905/28/2025To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER433731.0000000FOR433731.000000FORS000002106Arcellx, Inc.03940C100US03940C100905/28/2025To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER433731.0000000FOR433731.000000FORS000002106Penumbra, Inc.70975L107US70975L107005/28/2025To elect the nominees for Class I director to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Janet LeedsDIRECTOR ELECTIONSISSUER157463.0000000FOR157463.000000FORS000002106Penumbra, Inc.70975L107US70975L107005/28/2025To elect the nominees for Class I director to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Thomas WilderDIRECTOR ELECTIONSISSUER157463.0000000FOR157463.000000FORS000002106Penumbra, Inc.70975L107US70975L107005/28/2025To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Penumbra, Inc. for the fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER157463.0000000FOR157463.000000FORS000002106Penumbra, Inc.70975L107US70975L107005/28/2025To approve, on an advisory basis, the compensation of Penumbra, Inc.'s named executive officers as disclosed in the proxy statement;SECTION 14A SAY-ON-PAY VOTESISSUER157463.0000000FOR157463.000000FORS000002106Penumbra, Inc.70975L107US70975L107005/28/2025To approve an amendment to Penumbra, Inc.'s Restated Certificate of Incorporation to phase in the declassification of Penumbra, Inc.'s Board of Directors, andSHAREHOLDER RIGHTS AND DEFENSESISSUER157463.0000000FOR157463.000000FORS000002106Penumbra, Inc.70975L107US70975L107005/28/2025To approve an amendment to Penumbra, Inc.'s Restated Certificate of Incorporation to eliminate the supermajority voting requirements.CORPORATE GOVERNANCEISSUER157463.0000000FOR157463.000000FORS000002106Mirum Pharmaceuticals, Inc.604749101US604749101305/29/2025To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Christopher PeetzDIRECTOR ELECTIONSISSUER711866.0000000FOR711866.000000FORS000002106Mirum Pharmaceuticals, Inc.604749101US604749101305/29/2025To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Laura BregeDIRECTOR ELECTIONSISSUER711866.0000000FOR711866.000000FORS000002106Mirum Pharmaceuticals, Inc.604749101US604749101305/29/2025To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Michael GreyDIRECTOR ELECTIONSISSUER711866.0000000FOR711866.000000FORS000002106Mirum Pharmaceuticals, Inc.604749101US604749101305/29/2025To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER711866.0000000FOR711866.000000FORS000002106Mirum Pharmaceuticals, Inc.604749101US604749101305/29/2025To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER711866.0000000FOR711866.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025ELECTION OF DIRECTORS: Election of Director: Lonny J. CarpenterDIRECTOR ELECTIONSISSUER1009006.0000000FOR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025ELECTION OF DIRECTORS: Election of Director: Matthijs GlastraDIRECTOR ELECTIONSISSUER1009006.0000000FOR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025ELECTION OF DIRECTORS: Election of Director: Barbara B. HulitDIRECTOR ELECTIONSISSUER1009006.0000000FOR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025ELECTION OF DIRECTORS: Election of Director: R. Matthew JohnsonDIRECTOR ELECTIONSISSUER1009006.0000000FOR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025ELECTION OF DIRECTORS: Election of Director: Mary Kay LadoneDIRECTOR ELECTIONSISSUER1009006.0000000FOR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025ELECTION OF DIRECTORS: Election of Director: Maxine L. MauricioDIRECTOR ELECTIONSISSUER1009006.0000000FOR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025ELECTION OF DIRECTORS: Election of Director: Thomas N. SecorDIRECTOR ELECTIONSISSUER1009006.0000000FOR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025ELECTION OF DIRECTORS: Election of Director: Darlene J.S. SolomonDIRECTOR ELECTIONSISSUER1009006.0000000FOR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025ELECTION OF DIRECTORS: Election of Director: Frank A. WilsonDIRECTOR ELECTIONSISSUER1009006.0000000FOR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025Approval, on an advisory (non-binding) basis, of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1009006.0000000FOR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025Approval, on an advisory (non-binding) basis, the frequency of future shareholder votes on the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1009006.0000000ONE YEAR1009006.000000FORS000002106Novanta Inc.67000B104CA67000B104005/29/2025To appoint Deloitte & Touche LLP as the Company's independent registered public accounting firm to serve until the 2025 Annual Meeting of Shareholders.AUDIT-RELATEDISSUER1009006.0000000FOR1009006.000000FORS000002106Dyne Therapeutics, Inc.26818M108US26818M108005/30/2025To elect two Class II directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Edward HurwitzDIRECTOR ELECTIONSISSUER846359.0000000FOR846359.000000FORS000002106Dyne Therapeutics, Inc.26818M108US26818M108005/30/2025To elect two Class II directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Dirk KerstenDIRECTOR ELECTIONSISSUER846359.0000000FOR846359.000000FORS000002106Dyne Therapeutics, Inc.26818M108US26818M108005/30/2025To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER846359.0000000FOR846359.000000FORS000002106Dyne Therapeutics, Inc.26818M108US26818M108005/30/2025To hold an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER846359.0000000ONE YEAR846359.000000FORS000002106Dyne Therapeutics, Inc.26818M108US26818M108005/30/2025To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER846359.0000000FOR846359.000000FORS000002106Day One Biopharmaceuticals, Inc.23954D109US23954D109006/02/2025Election of Class I Directors: Natalie HollesDIRECTOR ELECTIONSISSUER734067.0000000FOR734067.000000FORS000002106Day One Biopharmaceuticals, Inc.23954D109US23954D109006/02/2025Election of Class I Directors: Garry NicholsonDIRECTOR ELECTIONSISSUER734067.0000000FOR734067.000000FORS000002106Day One Biopharmaceuticals, Inc.23954D109US23954D109006/02/2025Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER734067.0000000FOR734067.000000FORS000002106Day One Biopharmaceuticals, Inc.23954D109US23954D109006/02/2025Approval, on a non-binding advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER734067.0000000FOR734067.000000FORS000002106Akero Therapeutics, Inc.00973Y108US00973Y108206/03/2025To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Judy Chou, Ph.D.DIRECTOR ELECTIONSISSUER1604505.0000000WITHHOLD1604505.000000AGAINSTS000002106Akero Therapeutics, Inc.00973Y108US00973Y108206/03/2025To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Tomas HeymanDIRECTOR ELECTIONSISSUER1604505.0000000WITHHOLD1604505.000000AGAINSTS000002106Akero Therapeutics, Inc.00973Y108US00973Y108206/03/2025To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1604505.0000000FOR1604505.000000FORS000002106Akero Therapeutics, Inc.00973Y108US00973Y108206/03/2025To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1604505.0000000FOR1604505.000000FORS000002106Datadog, Inc.23804L103US23804L103506/03/2025To elect three Class III directors, each to hold office until our Annual Meeting of Stockholders in 2028: Titi ColeDIRECTOR ELECTIONSISSUER2925101.0000000FOR2925101.000000FORS000002106Datadog, Inc.23804L103US23804L103506/03/2025To elect three Class III directors, each to hold office until our Annual Meeting of Stockholders in 2028: Matthew JacobsonDIRECTOR ELECTIONSISSUER2925101.0000000FOR2925101.000000FORS000002106Datadog, Inc.23804L103US23804L103506/03/2025To elect three Class III directors, each to hold office until our Annual Meeting of Stockholders in 2028: Julie RichardsonDIRECTOR ELECTIONSISSUER2925101.0000000FOR2925101.000000FORS000002106Datadog, Inc.23804L103US23804L103506/03/2025Advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2925101.0000000FOR2925101.000000FORS000002106Datadog, Inc.23804L103US23804L103506/03/2025To ratify the selection by the Audit Committee of our Board of Directors of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER2925101.0000000FOR2925101.000000FORS000002106Datadog, Inc.23804L103US23804L103506/03/2025To approve the amendment and restatement of our Amended and Restated Certificate of Incorporation to provide for the exculpation of officers as permitted by Delaware law and make additional non-substantive and clarifying changes.CORPORATE GOVERNANCEISSUER2925101.0000000AGAINST2925101.000000AGAINSTS000002106Denali Therapeutics Inc.24823R105US24823R105906/03/2025ELECTION OF DIRECTORS: Julian BakerDIRECTOR ELECTIONSISSUER578000.0000000FOR578000.000000FORS000002106Denali Therapeutics Inc.24823R105US24823R105906/03/2025ELECTION OF DIRECTORS: Peter KleinDIRECTOR ELECTIONSISSUER578000.0000000FOR578000.000000FORS000002106Denali Therapeutics Inc.24823R105US24823R105906/03/2025ELECTION OF DIRECTORS: Steve KrognesDIRECTOR ELECTIONSISSUER578000.0000000WITHHOLD578000.000000AGAINSTS000002106Denali Therapeutics Inc.24823R105US24823R105906/03/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025AUDIT-RELATEDISSUER578000.0000000FOR578000.000000FORS000002106Denali Therapeutics Inc.24823R105US24823R105906/03/2025Advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER578000.0000000FOR578000.000000FORS000002106Loar Holdings, Inc.53947R105US53947R105906/03/2025Election of Dirkson Charles, Anthony M. Carpenito, Taiwo Danmola and Paul S. Levy as Class 1 directors, each to hold office until our annual meeting of stockholders in 2028 and until their successor is duly elected and qualified, or until their earlier death, resignation, or removal: Dirkson CharlesDIRECTOR ELECTIONSISSUER434024.0000000FOR434024.000000FORS000002106Loar Holdings, Inc.53947R105US53947R105906/03/2025Election of Dirkson Charles, Anthony M. Carpenito, Taiwo Danmola and Paul S. Levy as Class 1 directors, each to hold office until our annual meeting of stockholders in 2028 and until their successor is duly elected and qualified, or until their earlier death, resignation, or removal: Anthony M. CarpenitoDIRECTOR ELECTIONSISSUER434024.0000000FOR434024.000000FORS000002106Loar Holdings, Inc.53947R105US53947R105906/03/2025Election of Dirkson Charles, Anthony M. Carpenito, Taiwo Danmola and Paul S. Levy as Class 1 directors, each to hold office until our annual meeting of stockholders in 2028 and until their successor is duly elected and qualified, or until their earlier death, resignation, or removal: Taiwo DanmolaDIRECTOR ELECTIONSISSUER434024.0000000FOR434024.000000FORS000002106Loar Holdings, Inc.53947R105US53947R105906/03/2025Election of Dirkson Charles, Anthony M. Carpenito, Taiwo Danmola and Paul S. Levy as Class 1 directors, each to hold office until our annual meeting of stockholders in 2028 and until their successor is duly elected and qualified, or until their earlier death, resignation, or removal: Paul S. LevyDIRECTOR ELECTIONSISSUER434024.0000000FOR434024.000000FORS000002106Loar Holdings, Inc.53947R105US53947R105906/03/2025Ratification of the appointment of Ernst & Young LLP ("EY") as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER434024.0000000FOR434024.000000FORS000002106Loar Holdings, Inc.53947R105US53947R105906/03/2025Approval of Amended and Restated Loar Holdings Inc. 2024 Equity Incentive Plan.COMPENSATIONISSUER434024.0000000FOR434024.000000FORS000002106Beam Therapeutics Inc.07373V105US07373V105206/04/2025Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Mark Fishman, M.D.DIRECTOR ELECTIONSISSUER280454.0000000FOR280454.000000FORS000002106Beam Therapeutics Inc.07373V105US07373V105206/04/2025Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Carole Ho, M.D.DIRECTOR ELECTIONSISSUER280454.0000000FOR280454.000000FORS000002106Beam Therapeutics Inc.07373V105US07373V105206/04/2025Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Kathleen WalshDIRECTOR ELECTIONSISSUER280454.0000000FOR280454.000000FORS000002106Beam Therapeutics Inc.07373V105US07373V105206/04/2025Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER280454.0000000FOR280454.000000FORS000002106Beam Therapeutics Inc.07373V105US07373V105206/04/2025Approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER280454.0000000FOR280454.000000FORS000002106Generation Bio Co.37148K209US37148K209606/04/2025Election of three Class II directors to our board of directors, each to serve until the 2028 Annual Meeting of Stockholders: Ron CooperDIRECTOR ELECTIONSISSUER4949019.0000000FOR4949019.000000FORS000002106Generation Bio Co.37148K209US37148K209606/04/2025Election of three Class II directors to our board of directors, each to serve until the 2028 Annual Meeting of Stockholders: Anthony Quinn, M.B. Ch. N., Ph.D.DIRECTOR ELECTIONSISSUER4949019.0000000FOR4949019.000000FORS000002106Generation Bio Co.37148K209US37148K209606/04/2025Election of three Class II directors to our board of directors, each to serve until the 2028 Annual Meeting of Stockholders: Jason RhodesDIRECTOR ELECTIONSISSUER4949019.0000000FOR4949019.000000FORS000002106Generation Bio Co.37148K209US37148K209606/04/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER4949019.0000000FOR4949019.000000FORS000002106Generation Bio Co.37148K209US37148K209606/04/2025Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4949019.0000000FOR4949019.000000FORS000002106Generation Bio Co.37148K209US37148K209606/04/2025Adoption and approval of an amendment to our restated certificate of incorporation to effect a reverse stock split of our issued shares of common stock at a ratio within the range of not less than 1-for-10 and not greater than 1-for-30, without reducing the authorized number of shares of our common stock, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of our board of directors, without further approval or authorization of our stockholders.CAPITAL STRUCTUREISSUER4949019.0000000FOR4949019.000000FORS000002106HubSpot, Inc.443573100US443573100906/04/2025Elect three Class II directors to hold office until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal: Lorrie M. NorringtonDIRECTOR ELECTIONSISSUER753294.0000000FOR753294.000000FORS000002106HubSpot, Inc.443573100US443573100906/04/2025Elect three Class II directors to hold office until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal: Andrew AnagnostDIRECTOR ELECTIONSISSUER753294.0000000FOR753294.000000FORS000002106HubSpot, Inc.443573100US443573100906/04/2025Elect three Class II directors to hold office until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal: Dharmesh ShahDIRECTOR ELECTIONSISSUER753294.0000000FOR753294.000000FORS000002106HubSpot, Inc.443573100US443573100906/04/2025Ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER753294.0000000FOR753294.000000FORS000002106HubSpot, Inc.443573100US443573100906/04/2025Non-binding advisory vote to approve the compensation of the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER753294.0000000FOR753294.000000FORS000002106HubSpot, Inc.443573100US443573100906/04/2025Approve amendments to the HubSpot, Inc. Seventh Amended and Restated Certificate of Incorporation to declassify the Company's Board of Directors; andSHAREHOLDER RIGHTS AND DEFENSESISSUER753294.0000000FOR753294.000000FORS000002106HubSpot, Inc.443573100US443573100906/04/2025Approve amendments to the HubSpot, Inc. Seventh Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions.CORPORATE GOVERNANCEISSUER753294.0000000FOR753294.000000FORS000002106HubSpot, Inc.443573100US443573100906/04/2025A stockholder proposal to change to a simple majority standard in connection with each voting requirement in the Company's certificate of incorporation and bylaws.CORPORATE GOVERNANCESECURITY HOLDER753294.0000000AGAINST753294.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Anthony S. MarucciDIRECTOR ELECTIONSISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Keith L. BrownlieDIRECTOR ELECTIONSISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Cheryl L. CohenDIRECTOR ELECTIONSISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Herbert J. ConradDIRECTOR ELECTIONSISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Rita I. Jain, M.D.DIRECTOR ELECTIONSISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: James J. MarinoDIRECTOR ELECTIONSISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Garry Neil, M.D.DIRECTOR ELECTIONSISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Harry H. Penner, Jr.DIRECTOR ELECTIONSISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Denice TorresDIRECTOR ELECTIONSISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025To approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of shares reserved for issuance thereunder by 2,000,000 shares to 9,500,000 shares.COMPENSATIONISSUER1510302.0000000FOR1510302.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1510302.0000000FOR1510302.000000FORS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025Election of Directors: Allene M. DiazDIRECTOR ELECTIONSISSUER1115663.0000000AGAINST1115663.000000AGAINSTS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025Election of Directors: Michael HaydenDIRECTOR ELECTIONSISSUER1115663.0000000AGAINST1115663.000000AGAINSTS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025Election of Directors: Joseph Klein, IIIDIRECTOR ELECTIONSISSUER1115663.0000000AGAINST1115663.000000AGAINSTS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025Election of Directors: Joseph LoscalzoDIRECTOR ELECTIONSISSUER1115663.0000000AGAINST1115663.000000AGAINSTS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025To make an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1115663.0000000FOR1115663.000000FORS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 4,000,000 shares to an aggregate of 42,500,000 shares.COMPENSATIONISSUER1115663.0000000FOR1115663.000000FORS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2025 fiscal year.AUDIT-RELATEDISSUER1115663.0000000FOR1115663.000000FORS000002106MoonLake Immunotherapeutics61559X104KY61559X104506/05/2025Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Jorge Santos da SilvaDIRECTOR ELECTIONSISSUER597447.0000000FOR597447.000000FORS000002106MoonLake Immunotherapeutics61559X104KY61559X104506/05/2025Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Simon SturgeDIRECTOR ELECTIONSISSUER597447.0000000FOR597447.000000FORS000002106MoonLake Immunotherapeutics61559X104KY61559X104506/05/2025Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Andrew PhillipsDIRECTOR ELECTIONSISSUER597447.0000000FOR597447.000000FORS000002106MoonLake Immunotherapeutics61559X104KY61559X104506/05/2025Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER597447.0000000FOR597447.000000FORS000002106MoonLake Immunotherapeutics61559X104KY61559X104506/05/2025Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER597447.0000000FOR597447.000000FORS000002106Procore Technologies, Inc.74275K108US74275K108806/05/2025To elect three Class I directors, each to hold office until the Company's 2028 annual meeting of stockholders: Erin M. ChappleDIRECTOR ELECTIONSISSUER2024074.0000000FOR2024074.000000FORS000002106Procore Technologies, Inc.74275K108US74275K108806/05/2025To elect three Class I directors, each to hold office until the Company's 2028 annual meeting of stockholders: Brian FeinsteinDIRECTOR ELECTIONSISSUER2024074.0000000FOR2024074.000000FORS000002106Procore Technologies, Inc.74275K108US74275K108806/05/2025To elect three Class I directors, each to hold office until the Company's 2028 annual meeting of stockholders: Kevin J. O'ConnorDIRECTOR ELECTIONSISSUER2024074.0000000FOR2024074.000000FORS000002106Procore Technologies, Inc.74275K108US74275K108806/05/2025To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER2024074.0000000FOR2024074.000000FORS000002106Procore Technologies, Inc.74275K108US74275K108806/05/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2024074.0000000FOR2024074.000000FORS000002106Soleno Therapeutics, Inc.834203309US834203309406/05/2025To elect two Class II directors to each serve until the 2028 Annual Meeting of stockholders or until his successor is duly elected and qualified: Anish Bhatnagar, M.D.DIRECTOR ELECTIONSISSUER393252.0000000FOR393252.000000FORS000002106Soleno Therapeutics, Inc.834203309US834203309406/05/2025To elect two Class II directors to each serve until the 2028 Annual Meeting of stockholders or until his successor is duly elected and qualified: William G. HarrisDIRECTOR ELECTIONSISSUER393252.0000000WITHHOLD393252.000000AGAINSTS000002106Soleno Therapeutics, Inc.834203309US834203309406/05/2025To ratify the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER393252.0000000FOR393252.000000FORS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Gunther BrightDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: James CoulterDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Mary CranstonDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Kelvin DavisDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Kathy ElsesserDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Deborah MessemerDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Nehal RajDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Jeffrey RhodesDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Ganendran SarvananthanDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Todd SisitskyDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: David TrujilloDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Anilu Vazquez-UbarriDIRECTOR ELECTIONSISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Directors: Jon WinkelriedDIRECTOR ELECTIONSISSUER172072.0000000FOR172072.000000FORS000002106TPG Inc.872657101US872657101606/05/2025Election of Executive Committee Members: James CoulterDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Executive Committee Members: Kelvin DavisDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Executive Committee Members: Nehal RajDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Executive Committee Members: Jeffrey RhodesDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Executive Committee Members: Ganendran SarvananthanDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Executive Committee Members: Todd SisitskyDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Executive Committee Members: David TrujilloDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Executive Committee Members: Anilu Vazquez-UbarriDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER172072.0000000WITHHOLD172072.000000AGAINSTS000002106TPG Inc.872657101US872657101606/05/2025Election of Executive Committee Members: Jon WinkelriedDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER172072.0000000FOR172072.000000FORS000002106TPG Inc.872657101US872657101606/05/2025Ratification of Deloitte & Touche LLP as our Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER172072.0000000FOR172072.000000FORS000002106Relay Therapeutics, Inc.75943R102US75943R102306/06/2025To elect the two class II directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Alexis BorisyDIRECTOR ELECTIONSISSUER1487277.0000000FOR1487277.000000FORS000002106Relay Therapeutics, Inc.75943R102US75943R102306/06/2025To elect the two class II directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Mark Murcko, Ph.D.DIRECTOR ELECTIONSISSUER1487277.0000000FOR1487277.000000FORS000002106Relay Therapeutics, Inc.75943R102US75943R102306/06/2025To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1487277.0000000FOR1487277.000000FORS000002106Relay Therapeutics, Inc.75943R102US75943R102306/06/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; andAUDIT-RELATEDISSUER1487277.0000000FOR1487277.000000FORS000002106Bicara Therapeutics Inc.055477103US055477103206/09/2025To elect three class I directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Kiran Mazumdar-ShawDIRECTOR ELECTIONSISSUER527463.0000000WITHHOLD527463.000000AGAINSTS000002106Bicara Therapeutics Inc.055477103US055477103206/09/2025To elect three class I directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Jake Simson, Ph.D.DIRECTOR ELECTIONSISSUER527463.0000000FOR527463.000000FORS000002106Bicara Therapeutics Inc.055477103US055477103206/09/2025To elect three class I directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Ryan Cohlhepp, Pharm D.DIRECTOR ELECTIONSISSUER527463.0000000FOR527463.000000FORS000002106Bicara Therapeutics Inc.055477103US055477103206/09/2025To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; andAUDIT-RELATEDISSUER527463.0000000FOR527463.000000FORS000002106Reddit, Inc.75734B100US75734B100806/09/2025Election of Directors: Steven HuffmanDIRECTOR ELECTIONSISSUER249100.0000000FOR249100.000000FORS000002106Reddit, Inc.75734B100US75734B100806/09/2025Election of Directors: Sarah FarrellDIRECTOR ELECTIONSISSUER249100.0000000FOR249100.000000FORS000002106Reddit, Inc.75734B100US75734B100806/09/2025Election of Directors: Patricia Fili-KrushelDIRECTOR ELECTIONSISSUER249100.0000000FOR249100.000000FORS000002106Reddit, Inc.75734B100US75734B100806/09/2025Election of Directors: Porter GaleDIRECTOR ELECTIONSISSUER249100.0000000FOR249100.000000FORS000002106Reddit, Inc.75734B100US75734B100806/09/2025Election of Directors: David HabigerDIRECTOR ELECTIONSISSUER249100.0000000FOR249100.000000FORS000002106Reddit, Inc.75734B100US75734B100806/09/2025Election of Directors: Steven O. NewhouseDIRECTOR ELECTIONSISSUER249100.0000000WITHHOLD249100.000000AGAINSTS000002106Reddit, Inc.75734B100US75734B100806/09/2025Election of Directors: Robert A. SauerbergDIRECTOR ELECTIONSISSUER249100.0000000WITHHOLD249100.000000AGAINSTS000002106Reddit, Inc.75734B100US75734B100806/09/2025Election of Directors: Michael SeibelDIRECTOR ELECTIONSISSUER249100.0000000WITHHOLD249100.000000AGAINSTS000002106Reddit, Inc.75734B100US75734B100806/09/2025Ratification of the appointment KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER249100.0000000FOR249100.000000FORS000002106Reddit, Inc.75734B100US75734B100806/09/2025Advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER249100.0000000FOR249100.000000FORS000002106Reddit, Inc.75734B100US75734B100806/09/2025Advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER249100.0000000ONE YEAR249100.000000FORS000002106Avidity Biosciences, Inc.05370A108US05370A108806/10/2025To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Arthur Levin, Ph.D.DIRECTOR ELECTIONSISSUER3970776.0000000FOR3970776.000000FORS000002106Avidity Biosciences, Inc.05370A108US05370A108806/10/2025To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Simona SkerjanecDIRECTOR ELECTIONSISSUER3970776.0000000FOR3970776.000000FORS000002106Avidity Biosciences, Inc.05370A108US05370A108806/10/2025To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Tamar ThompsonDIRECTOR ELECTIONSISSUER3970776.0000000FOR3970776.000000FORS000002106Avidity Biosciences, Inc.05370A108US05370A108806/10/2025To ratify the appointment of Deloitte & Touche LLP as our independent public accounting firm for the fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER3970776.0000000FOR3970776.000000FORS000002106Avidity Biosciences, Inc.05370A108US05370A108806/10/2025To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; andSECTION 14A SAY-ON-PAY VOTESISSUER3970776.0000000FOR3970776.000000FORS000002106PROCEPT BioRobotics Corporation74276L105US74276L105206/10/2025Election of Class I directors to serve until 2028 annual meeting of shareholders and until their successors are duly elected and qualified: Elisabeth LittleDIRECTOR ELECTIONSISSUER125839.0000000FOR125839.000000FORS000002106PROCEPT BioRobotics Corporation74276L105US74276L105206/10/2025Election of Class I directors to serve until 2028 annual meeting of shareholders and until their successors are duly elected and qualified: Thomas M. PrescottDIRECTOR ELECTIONSISSUER125839.0000000FOR125839.000000FORS000002106PROCEPT BioRobotics Corporation74276L105US74276L105206/10/2025Election of Class I directors to serve until 2028 annual meeting of shareholders and until their successors are duly elected and qualified: Larry WoodDIRECTOR ELECTIONSISSUER125839.0000000FOR125839.000000FORS000002106PROCEPT BioRobotics Corporation74276L105US74276L105206/10/2025Ratification of the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for PROCEPT for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER125839.0000000FOR125839.000000FORS000002106PROCEPT BioRobotics Corporation74276L105US74276L105206/10/2025Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER125839.0000000FOR125839.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Election of nine director nominees for a one-year term: Shellye L. ArchambeauDIRECTOR ELECTIONSISSUER483729.0000000FOR483729.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Election of nine director nominees for a one-year term: Amy Woods BrinkleyDIRECTOR ELECTIONSISSUER483729.0000000FOR483729.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Election of nine director nominees for a one-year term: Irene M. EstevesDIRECTOR ELECTIONSISSUER483729.0000000FOR483729.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Election of nine director nominees for a one-year term: L. Neil HunnDIRECTOR ELECTIONSISSUER483729.0000000FOR483729.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Election of nine director nominees for a one-year term: Robert D. JohnsonDIRECTOR ELECTIONSISSUER483729.0000000FOR483729.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Election of nine director nominees for a one-year term: Thomas P. Joyce, Jr.DIRECTOR ELECTIONSISSUER483729.0000000FOR483729.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Election of nine director nominees for a one-year term: John F. MurphyDIRECTOR ELECTIONSISSUER483729.0000000FOR483729.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Election of nine director nominees for a one-year term: Laura G. ThatcherDIRECTOR ELECTIONSISSUER483729.0000000FOR483729.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Election of nine director nominees for a one-year term: Richard F. WallmanDIRECTOR ELECTIONSISSUER483729.0000000FOR483729.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER483729.0000000FOR483729.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/10/2025Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER483729.0000000FOR483729.000000FORS000002106Zenas BioPharma, Inc.98937L105US98937L105206/10/2025To elect the two Class I director nominees named in the Proxy Statement to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Leon O. Moulder, Jr.DIRECTOR ELECTIONSISSUER324072.0000000FOR324072.000000FORS000002106Zenas BioPharma, Inc.98937L105US98937L105206/10/2025To elect the two Class I director nominees named in the Proxy Statement to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Hongbo Lu, Ph.D.DIRECTOR ELECTIONSISSUER324072.0000000FOR324072.000000FORS000002106Zenas BioPharma, Inc.98937L105US98937L105206/10/2025To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER324072.0000000FOR324072.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Annabelle BexigaDIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Ronald F. ClarkeDIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Joseph W. FarrellyDIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Rahul GuptaDIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Thomas M. HagertyDIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Archie L. Jones, Jr.DIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Richard MacchiaDIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Hala G. ModdelmogDIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Jeffrey S. SloanDIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Steven T. StullDIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Elect Directors nominated by the Board of Directors for a one-year term: Gerald ThroopDIRECTOR ELECTIONSISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Ratify the re-appointment of Ernst & Young LLP as Corpay's independent public accounting firm for 2025.AUDIT-RELATEDISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1074732.0000000FOR1074732.000000FORS000002106Corpay, Inc.219948106US219948106806/11/2025Shareholder proposal regarding an independent Board chair requirement, if properly presented at the meeting.CORPORATE GOVERNANCESECURITY HOLDER1074732.0000000AGAINST1074732.000000FORS000002106Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/11/2025To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Matthew K. FustDIRECTOR ELECTIONSISSUER1919922.0000000FOR1919922.000000FORS000002106Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/11/2025To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: R. Scott Struthers, Ph.D.DIRECTOR ELECTIONSISSUER1919922.0000000FOR1919922.000000FORS000002106Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/11/2025To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Rogerio Vivaldi Coelho, M.D.DIRECTOR ELECTIONSISSUER1919922.0000000FOR1919922.000000FORS000002106Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/11/2025To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER1919922.0000000FOR1919922.000000FORS000002106Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/11/2025To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;SECTION 14A SAY-ON-PAY VOTESISSUER1919922.0000000FOR1919922.000000FORS000002106Disc Medicine, Inc.254604101US254604101106/11/2025To elect each of the following Class II nominees to the Board of Directors as set forth below: Georges Gemayel, Ph.D.DIRECTOR ELECTIONSISSUER478807.0000000FOR478807.000000FORS000002106Disc Medicine, Inc.254604101US254604101106/11/2025To elect each of the following Class II nominees to the Board of Directors as set forth below: Mark Chin, M.S., M.B.A.DIRECTOR ELECTIONSISSUER478807.0000000FOR478807.000000FORS000002106Disc Medicine, Inc.254604101US254604101106/11/2025To elect each of the following Class II nominees to the Board of Directors as set forth below: Liam Ratcliffe, M.D., Ph.D.DIRECTOR ELECTIONSISSUER478807.0000000FOR478807.000000FORS000002106Disc Medicine, Inc.254604101US254604101106/11/2025To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER478807.0000000FOR478807.000000FORS000002106Disc Medicine, Inc.254604101US254604101106/11/2025To recommend, by a non-binding advisory vote, the frequency of future advisory votes on the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER478807.0000000ONE YEAR478807.000000FORS000002106Disc Medicine, Inc.254604101US254604101106/11/2025To ratify the appointment of Emst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER478807.0000000FOR478807.000000FORS000002106Entrada Therapeutics, Inc.29384C108US29384C108006/11/2025Election of Directors: Dipal DoshiDIRECTOR ELECTIONSISSUER1530262.0000000FOR1530262.000000FORS000002106Entrada Therapeutics, Inc.29384C108US29384C108006/11/2025Election of Directors: Kush M. Parmar, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1530262.0000000FOR1530262.000000FORS000002106Entrada Therapeutics, Inc.29384C108US29384C108006/11/2025Election of Directors: Mary ThistleDIRECTOR ELECTIONSISSUER1530262.0000000FOR1530262.000000FORS000002106Entrada Therapeutics, Inc.29384C108US29384C108006/11/2025Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1530262.0000000FOR1530262.000000FORS000002106Janux Therapeutics, Inc.47103J105US47103J105106/11/2025To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Ronald Barrett, Ph.D.DIRECTOR ELECTIONSISSUER493097.0000000FOR493097.000000FORS000002106Janux Therapeutics, Inc.47103J105US47103J105106/11/2025To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: David Campbell, Ph.D.DIRECTOR ELECTIONSISSUER493097.0000000FOR493097.000000FORS000002106Janux Therapeutics, Inc.47103J105US47103J105106/11/2025To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Winston KungDIRECTOR ELECTIONSISSUER493097.0000000FOR493097.000000FORS000002106Janux Therapeutics, Inc.47103J105US47103J105106/11/2025To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER493097.0000000FOR493097.000000FORS000002106Janux Therapeutics, Inc.47103J105US47103J105106/11/2025Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER493097.0000000FOR493097.000000FORS000002106Janux Therapeutics, Inc.47103J105US47103J105106/11/2025Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER493097.0000000ONE YEAR493097.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025Election of Directors: Steven BeringhauseDIRECTOR ELECTIONSISSUER2082658.0000000FOR2082658.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025Election of Directors: Benjamin C. Duster, IVDIRECTOR ELECTIONSISSUER2082658.0000000FOR2082658.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025Election of Directors: Neal P. GoldmanDIRECTOR ELECTIONSISSUER2082658.0000000FOR2082658.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025Election of Directors: Jacqueline C. MutschlerDIRECTOR ELECTIONSISSUER2082658.0000000FOR2082658.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025Election of Directors: Girishchandra K. SaligramDIRECTOR ELECTIONSISSUER2082658.0000000FOR2082658.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025Election of Directors: Charles M. SledgeDIRECTOR ELECTIONSISSUER2082658.0000000FOR2082658.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm and auditor for the financial year ending December 31, 2025 and KPMG Chartered Accountants, Dublin, as the Company's statutory auditor under Irish law to hold office until the close of the 2026 AGM, and to authorize the Board of Directors of the Company, acting through the Audit Committee, to determine the auditors' remuneration.AUDIT-RELATEDISSUER2082658.0000000FOR2082658.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025To approve, on a non-binding advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER2082658.0000000FOR2082658.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025To approve the amendment and restatement of the Weatherford International pic Third Amended and Restated 2019 Equity Incentive Plan.COMPENSATIONISSUER2082658.0000000FOR2082658.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025To grant the Board authority to issue shares under Irish law.CAPITAL STRUCTUREISSUER2082658.0000000FOR2082658.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/11/2025To grant the Board the power to opt-out of statutory preemption rights under Irish law.CAPITAL STRUCTUREISSUER2082658.0000000FOR2082658.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/12/2025Election of Directors: Vicente ReynalDIRECTOR ELECTIONSISSUER4181649.0000000FOR4181649.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/12/2025Election of Directors: William P. DonnellyDIRECTOR ELECTIONSISSUER4181649.0000000FOR4181649.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/12/2025Election of Directors: Jennifer HartsockDIRECTOR ELECTIONSISSUER4181649.0000000FOR4181649.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/12/2025Election of Directors: John HumphreyDIRECTOR ELECTIONSISSUER4181649.0000000FOR4181649.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/12/2025Election of Directors: Marc E. JonesDIRECTOR ELECTIONSISSUER4181649.0000000FOR4181649.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/12/2025Election of Directors: JoAnna L. SohovichDIRECTOR ELECTIONSISSUER4181649.0000000FOR4181649.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/12/2025Election of Directors: Mark P. StevensonDIRECTOR ELECTIONSISSUER4181649.0000000FOR4181649.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/12/2025Election of Directors: Michelle SwanenburgDIRECTOR ELECTIONSISSUER4181649.0000000FOR4181649.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/12/2025Ratification of appointment of Deloitte & Touche LLP as our independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER4181649.0000000FOR4181649.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/12/2025Non-binding vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER4181649.0000000FOR4181649.000000FORS000002106Marqeta, Inc.57142B104US57142B104406/12/2025To elect the three Class I nominees for director named in the accompanying proxy statement to hold office until the annual meeting of stockholders in 2028 and until their successors have been duly elected and qualified, or until such director's earlier death, resignation or removal: Jason GardnerDIRECTOR ELECTIONSISSUER5931597.0000000FOR5931597.000000FORS000002106Marqeta, Inc.57142B104US57142B104406/12/2025To elect the three Class I nominees for director named in the accompanying proxy statement to hold office until the annual meeting of stockholders in 2028 and until their successors have been duly elected and qualified, or until such director's earlier death, resignation or removal: R. Mark GrafDIRECTOR ELECTIONSISSUER5931597.0000000FOR5931597.000000FORS000002106Marqeta, Inc.57142B104US57142B104406/12/2025To elect the three Class I nominees for director named in the accompanying proxy statement to hold office until the annual meeting of stockholders in 2028 and until their successors have been duly elected and qualified, or until such director's earlier death, resignation or removal: Wendy ThomasDIRECTOR ELECTIONSISSUER5931597.0000000FOR5931597.000000FORS000002106Marqeta, Inc.57142B104US57142B104406/12/2025To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER5931597.0000000FOR5931597.000000FORS000002106Marqeta, Inc.57142B104US57142B104406/12/2025To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5931597.0000000FOR5931597.000000FORS000002106Monolithic Power Systems, Inc.609839105US609839105406/12/2025Election of Directors: Herbert ChangDIRECTOR ELECTIONSISSUER517734.0000000FOR517734.000000FORS000002106Monolithic Power Systems, Inc.609839105US609839105406/12/2025Election of Directors: Michael HsingDIRECTOR ELECTIONSISSUER517734.0000000FOR517734.000000FORS000002106Monolithic Power Systems, Inc.609839105US609839105406/12/2025Election of Directors: Carintia MartinezDIRECTOR ELECTIONSISSUER517734.0000000FOR517734.000000FORS000002106Monolithic Power Systems, Inc.609839105US609839105406/12/2025Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER517734.0000000FOR517734.000000FORS000002106Monolithic Power Systems, Inc.609839105US609839105406/12/2025Approve, on an advisory basis, the 2024 executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER517734.0000000FOR517734.000000FORS000002106Monolithic Power Systems, Inc.609839105US609839105406/12/2025Vote on a management proposal to amend and restate our Amended and Restated Certificate of Incorporation to declassify the Board of Directors.SHAREHOLDER RIGHTS AND DEFENSESISSUER517734.0000000FOR517734.000000FORS000002106Monolithic Power Systems, Inc.609839105US609839105406/12/2025Vote on a stockholder proposal to give shareholders the ability to call for a special shareholder meeting.CORPORATE GOVERNANCESECURITY HOLDER517734.0000000AGAINST517734.000000FORS000002106Natera, Inc.632307104US632307104206/12/2025To elect the three directors named below and in the proxy statement to serve as Class I directors until the annual meeting of stockholders to be held in 2028 and until their successors are duly elected and qualified: Roy BaynesDIRECTOR ELECTIONSISSUER1599990.0000000FOR1599990.000000FORS000002106Natera, Inc.632307104US632307104206/12/2025To elect the three directors named below and in the proxy statement to serve as Class I directors until the annual meeting of stockholders to be held in 2028 and until their successors are duly elected and qualified: Gail MarcusDIRECTOR ELECTIONSISSUER1599990.0000000FOR1599990.000000FORS000002106Natera, Inc.632307104US632307104206/12/2025To elect the three directors named below and in the proxy statement to serve as Class I directors until the annual meeting of stockholders to be held in 2028 and until their successors are duly elected and qualified: Ruth Williams-BrinkleyDIRECTOR ELECTIONSISSUER1599990.0000000FOR1599990.000000FORS000002106Natera, Inc.632307104US632307104206/12/2025To ratify the appointment of Ernst & Young LLP as Natera, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1599990.0000000FOR1599990.000000FORS000002106Natera, Inc.632307104US632307104206/12/2025To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1599990.0000000FOR1599990.000000FORS000002106Natera, Inc.632307104US632307104206/12/2025To approve an amendment to Natera's Amended and Restated 2015 Equity Incentive Plan.COMPENSATIONISSUER1599990.0000000FOR1599990.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Elect Director Deepak ChopraDIRECTOR ELECTIONSISSUER1649946.0000000FOR1649946.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Elect Director Eric A. DemirianDIRECTOR ELECTIONSISSUER1649946.0000000FOR1649946.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Elect Director Dennis MapleDIRECTOR ELECTIONSISSUER1649946.0000000FOR1649946.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Elect Director Jane MowatDIRECTOR ELECTIONSISSUER1649946.0000000FOR1649946.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Elect Director Chris MuntwylerDIRECTOR ELECTIONSISSUER1649946.0000000FOR1649946.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Elect Director Jane O'HaganDIRECTOR ELECTIONSISSUER1649946.0000000FOR1649946.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Elect Director Edward J. RyanDIRECTOR ELECTIONSISSUER1649946.0000000FOR1649946.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Elect Director John J. WalkerDIRECTOR ELECTIONSISSUER1649946.0000000FOR1649946.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Elect Director Laura WilkinDIRECTOR ELECTIONSISSUER1649946.0000000FOR1649946.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Approve KPMG LLP as Auditors and Authorize Board to Fix Their RemunerationAUDIT-RELATEDISSUER1649946.0000000FOR1649946.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/12/2025Advisory Vote on Executive Compensation ApproachCOMPENSATIONISSUER1649946.0000000FOR1649946.000000FORS000002106Vaxcyte, Inc.92243G108US92243G108506/12/2025Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: John FureyDIRECTOR ELECTIONSISSUER1114742.0000000FOR1114742.000000FORS000002106Vaxcyte, Inc.92243G108US92243G108506/12/2025Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Jacks LeeDIRECTOR ELECTIONSISSUER1114742.0000000FOR1114742.000000FORS000002106Vaxcyte, Inc.92243G108US92243G108506/12/2025Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Heath Lukatch, Ph.D.DIRECTOR ELECTIONSISSUER1114742.0000000FOR1114742.000000FORS000002106Vaxcyte, Inc.92243G108US92243G108506/12/2025Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1114742.0000000FOR1114742.000000FORS000002106Vaxcyte, Inc.92243G108US92243G108506/12/2025Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1114742.0000000AGAINST1114742.000000AGAINSTS000002106Vaxcyte, Inc.92243G108US92243G108506/12/2025Approval of the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to provide for officer exculpation as permitted by recent amendments to the Delaware General Corporation Law.CORPORATE GOVERNANCEISSUER1114742.0000000FOR1114742.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Bassil I. DahiyatDIRECTOR ELECTIONSISSUER1447260.0000000FOR1447260.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Ellen G. FeigalDIRECTOR ELECTIONSISSUER1447260.0000000FOR1447260.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Kevin C. GormanDIRECTOR ELECTIONSISSUER1447260.0000000FOR1447260.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Kurt A. GustafsonDIRECTOR ELECTIONSISSUER1447260.0000000FOR1447260.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Barbara KlenckeDIRECTOR ELECTIONSISSUER1447260.0000000FOR1447260.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. A. Bruce MontgomeryDIRECTOR ELECTIONSISSUER1447260.0000000FOR1447260.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Richard J. RanieriDIRECTOR ELECTIONSISSUER1447260.0000000FOR1447260.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Todd E. SimpsonDIRECTOR ELECTIONSISSUER1447260.0000000FOR1447260.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER1447260.0000000FOR1447260.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To approve the proposed amendment and restatement of the Company's 2023 Equity Incentive Plan to increase the number of authorized shares reserved for issuance thereunder by 3,000,000 shares;COMPENSATIONISSUER1447260.0000000FOR1447260.000000FORS000002106Xencor, Inc.98401F105US98401F105706/12/2025To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement;SECTION 14A SAY-ON-PAY VOTESISSUER1447260.0000000FOR1447260.000000FORS000002106AppFolio, Inc.03783C100US03783C100906/13/2025Election of Class I Directors: Andreas von BlottnitzDIRECTOR ELECTIONSISSUER109449.0000000WITHHOLD109449.000000AGAINSTS000002106AppFolio, Inc.03783C100US03783C100906/13/2025Election of Class I Directors: Agnes Bundy ScanlanDIRECTOR ELECTIONSISSUER109449.0000000WITHHOLD109449.000000AGAINSTS000002106AppFolio, Inc.03783C100US03783C100906/13/2025Election of Class I Directors: Janet KerrDIRECTOR ELECTIONSISSUER109449.0000000WITHHOLD109449.000000AGAINSTS000002106AppFolio, Inc.03783C100US03783C100906/13/2025Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER109449.0000000FOR109449.000000FORS000002106AppFolio, Inc.03783C100US03783C100906/13/2025Advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER109449.0000000FOR109449.000000FORS000002106AppFolio, Inc.03783C100US03783C100906/13/2025Advisory vote on the frequency of future stockholder advisory votes to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER109449.0000000ONE YEAR109449.000000FORS000002106Monte Rosa Therapeutics, Inc.61225M102US61225M102706/13/2025To elect three Class I director nominees to our board of directors, to serve until the Company's 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Christine Siu, MBADIRECTOR ELECTIONSISSUER2929827.0000000FOR2929827.000000FORS000002106Monte Rosa Therapeutics, Inc.61225M102US61225M102706/13/2025To elect three Class I director nominees to our board of directors, to serve until the Company's 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Kimberly L. Blackwell, M.D.DIRECTOR ELECTIONSISSUER2929827.0000000FOR2929827.000000FORS000002106Monte Rosa Therapeutics, Inc.61225M102US61225M102706/13/2025To elect three Class I director nominees to our board of directors, to serve until the Company's 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Jan Skvarka, Ph.D., MBADIRECTOR ELECTIONSISSUER2929827.0000000FOR2929827.000000FORS000002106Monte Rosa Therapeutics, Inc.61225M102US61225M102706/13/2025To ratify the appointment of Deloitte & Touche, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; andAUDIT-RELATEDISSUER2929827.0000000FOR2929827.000000FORS000002106Toast, Inc.888787108US888787108006/13/2025Election of Directors: Paul BellDIRECTOR ELECTIONSISSUER15795850.0000000FOR15795850.000000FORS000002106Toast, Inc.888787108US888787108006/13/2025Election of Directors: Hilarie Koplow-McAdamsDIRECTOR ELECTIONSISSUER15795850.0000000FOR15795850.000000FORS000002106Toast, Inc.888787108US888787108006/13/2025Ratification of Appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER15795850.0000000FOR15795850.000000FORS000002106Toast, Inc.888787108US888787108006/13/2025To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER15795850.0000000FOR15795850.000000FORS000002106AnaptysBio, Inc.032724106US032724106506/17/2025To elect three Class II directors, each to serve three-year terms through the third annual meeting of stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal: Rita Jain, M.D.DIRECTOR ELECTIONSISSUER495034.0000000FOR495034.000000FORS000002106AnaptysBio, Inc.032724106US032724106506/17/2025To elect three Class II directors, each to serve three-year terms through the third annual meeting of stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal: John OrwinDIRECTOR ELECTIONSISSUER495034.0000000FOR495034.000000FORS000002106AnaptysBio, Inc.032724106US032724106506/17/2025To elect three Class II directors, each to serve three-year terms through the third annual meeting of stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal: J. Anthony Ware, M.D.DIRECTOR ELECTIONSISSUER495034.0000000FOR495034.000000FORS000002106AnaptysBio, Inc.032724106US032724106506/17/2025To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER495034.0000000FOR495034.000000FORS000002106AnaptysBio, Inc.032724106US032724106506/17/2025To conduct a non-binding advisory vote on the compensation of our named executive officers as disclosed in the accompanying materials.SECTION 14A SAY-ON-PAY VOTESISSUER495034.0000000AGAINST495034.000000AGAINSTS000002106AnaptysBio, Inc.032724106US032724106506/17/2025To approve an amendment to our 2017 Equity Incentive Plan.COMPENSATIONISSUER495034.0000000AGAINST495034.000000AGAINSTS000002106AnaptysBio, Inc.032724106US032724106506/17/2025Non-binding advisory vote on the frequency of holding future advisory votes regarding named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER495034.0000000ONE YEAR495034.000000FORS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2025To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Jacqualyn A. Fouse, Ph.D.DIRECTOR ELECTIONSISSUER379526.0000000FOR379526.000000FORS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2025To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: David Scadden, M.D.DIRECTOR ELECTIONSISSUER379526.0000000FOR379526.000000FORS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2025To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER379526.0000000FOR379526.000000FORS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2025To approve an amendment to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan, to increase the number of shares of common stock available thereunder by 2,500,000 shares.COMPENSATIONISSUER379526.0000000FOR379526.000000FORS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2025To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER379526.0000000FOR379526.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/18/2025Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: Jeffrey AlbersDIRECTOR ELECTIONSISSUER1778971.0000000FOR1778971.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/18/2025Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: Mark Goldberg, M.D.DIRECTOR ELECTIONSISSUER1778971.0000000FOR1778971.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/18/2025Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: John Tsai, M.D.DIRECTOR ELECTIONSISSUER1778971.0000000FOR1778971.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/18/2025Approval of a non-binding advisory vote on the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1778971.0000000FOR1778971.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/18/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1778971.0000000FOR1778971.000000FORS000002106Nuvalent, Inc.670703107US670703107506/18/2025Election of the following nominees as Class I directors: Grant BogleDIRECTOR ELECTIONSISSUER449514.0000000FOR449514.000000FORS000002106Nuvalent, Inc.670703107US670703107506/18/2025Election of the following nominees as Class I directors: James R. Porter, Ph.D.DIRECTOR ELECTIONSISSUER449514.0000000FOR449514.000000FORS000002106Nuvalent, Inc.670703107US670703107506/18/2025Election of the following nominees as Class I directors: Anna ProtopapasDIRECTOR ELECTIONSISSUER449514.0000000FOR449514.000000FORS000002106Nuvalent, Inc.670703107US670703107506/18/2025To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER449514.0000000AGAINST449514.000000AGAINSTS000002106Nuvalent, Inc.670703107US670703107506/18/2025To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER449514.0000000FOR449514.000000FORS000002106ServiceTitan, Inc.81764X103US81764X103706/18/2025To elect three Class I directors to serve until our 2028 annual meeting of stockholders and until their successors are duly elected and qualified: Tim CabralDIRECTOR ELECTIONSISSUER69602.0000000FOR69602.000000FORS000002106ServiceTitan, Inc.81764X103US81764X103706/18/2025To elect three Class I directors to serve until our 2028 annual meeting of stockholders and until their successors are duly elected and qualified: William HsuDIRECTOR ELECTIONSISSUER69602.0000000WITHHOLD69602.000000AGAINSTS000002106ServiceTitan, Inc.81764X103US81764X103706/18/2025To elect three Class I directors to serve until our 2028 annual meeting of stockholders and until their successors are duly elected and qualified: Ara MahdessianDIRECTOR ELECTIONSISSUER69602.0000000FOR69602.000000FORS000002106ServiceTitan, Inc.81764X103US81764X103706/18/2025To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending January 31, 2026.AUDIT-RELATEDISSUER69602.0000000FOR69602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Tim CabralDIRECTOR ELECTIONSISSUER2291811.0000000FOR2291811.000000FORS000002106Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Mark CargesDIRECTOR ELECTIONSISSUER2291811.0000000FOR2291811.000000FORS000002106Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Peter P. GassnerDIRECTOR ELECTIONSISSUER2291811.0000000FOR2291811.000000FORS000002106Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Mary Lynne HedleyDIRECTOR ELECTIONSISSUER2291811.0000000FOR2291811.000000FORS000002106Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Priscilla HungDIRECTOR ELECTIONSISSUER2291811.0000000FOR2291811.000000FORS000002106Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Marshall MohrDIRECTOR ELECTIONSISSUER2291811.0000000FOR2291811.000000FORS000002106Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Gordon RitterDIRECTOR ELECTIONSISSUER2291811.0000000FOR2291811.000000FORS000002106Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Paul SekhriDIRECTOR ELECTIONSISSUER2291811.0000000FOR2291811.000000FORS000002106Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Matthew J. WallachDIRECTOR ELECTIONSISSUER2291811.0000000FOR2291811.000000FORS000002106Veeva Systems Inc.922475108US922475108406/18/2025To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending January 31, 2026.AUDIT-RELATEDISSUER2291811.0000000FOR2291811.000000FORS000002106Cava Group, Inc.148929102US148929102106/20/2025Election of Class II Directors: Benjamin FeltDIRECTOR ELECTIONSISSUER1289110.0000000FOR1289110.000000FORS000002106Cava Group, Inc.148929102US148929102106/20/2025Election of Class II Directors: Ronald ShaichDIRECTOR ELECTIONSISSUER1289110.0000000FOR1289110.000000FORS000002106Cava Group, Inc.148929102US148929102106/20/2025Election of Class II Directors: Theodoros XenohristosDIRECTOR ELECTIONSISSUER1289110.0000000FOR1289110.000000FORS000002106Cava Group, Inc.148929102US148929102106/20/2025Approval of, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1289110.0000000FOR1289110.000000FORS000002106Cava Group, Inc.148929102US148929102106/20/2025Approval of, on an advisory basis, the frequency of future advisory votes to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1289110.0000000ONE YEAR1289110.000000FORS000002106Cava Group, Inc.148929102US148929102106/20/2025Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 28, 2025.AUDIT-RELATEDISSUER1289110.0000000FOR1289110.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To re-appoint as a director Arjun Goyal, M.D., M.Phil., M.B.A., who retires by rotation in accordance with the Company's articles of association.DIRECTOR ELECTIONSISSUER683023.0000000FOR683023.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To re-appoint as a director Samarth Kulkarni, Ph.D., who retires by rotation in accordance with the Company's articles of association.DIRECTOR ELECTIONSISSUER683023.0000000FOR683023.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To re-appoint KPMG LLP, a United Kingdom entity, as UK statutory auditors of the Company, to hold office until the conclusion of the next meeting at which the Company's annual accounts and reports are laid before the Company.AUDIT-RELATEDISSUER683023.0000000FOR683023.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To ratify the re-appointment of KPMG LLP, a Delaware limited liability partnership, as the Company's independent registered public accounting firm, for the financial year ending December 31, 2025.AUDIT-RELATEDISSUER683023.0000000FOR683023.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To authorize the Audit Committee to determine the Company's auditors' remuneration for the financial year ending December 31, 2025.AUDIT-RELATEDISSUER683023.0000000FOR683023.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To receive and adopt our UK statutory annual accounts and reports for the financial year ended December 31, 2024 and to note that the Company's directors do not recommend the payment of any dividend for the financial year ended December 31, 2024.CORPORATE GOVERNANCEISSUER683023.0000000FOR683023.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To receive and approve, on an advisory basis, the Company's U.K. statutory directors' remuneration report for the financial year ended December 31, 2024, which is set forth as Annex A to the proxy statement.COMPENSATIONISSUER683023.0000000FOR683023.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To receive and approve the Directors' Remuneration Policy as set out in the Company's UK statutory directors' remuneration report for the financial year ended December 31, 2024, which is set forth as Annex A to the proxy statement.COMPENSATIONISSUER683023.0000000FOR683023.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To generally and unconditionally authorise the directors of the Company or any duly authorised committee of the directors, in accordance with section 551 of the UK Companies Act 2006 (the "Companies Act"), to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of pounds133,184.CAPITAL STRUCTUREISSUER683023.0000000FOR683023.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/20/2025Subject to the passing of Resolution 9, to empower the Board of Directors to allot equity securities for cash, under section 570 of the Companies Act as if section 561(1) of the Companies Act did not apply to such allotment up to a maximum aggregate nominal amount of pounds133,184.CAPITAL STRUCTUREISSUER683023.0000000AGAINST683023.000000AGAINSTS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Re-election of Class III directors: Julian BakerDIRECTOR ELECTIONSISSUER164002.0000000WITHHOLD164002.000000AGAINSTS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Re-election of Class III directors: Raymond Cheong, M.D., Ph.D.DIRECTOR ELECTIONSISSUER164002.0000000WITHHOLD164002.000000AGAINSTS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Re-election of Class III directors: Jacqualyn Fouse, Ph.D.DIRECTOR ELECTIONSISSUER164002.0000000FOR164002.000000FORS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Re-election of Class III directors: Richard Levy, M.D.DIRECTOR ELECTIONSISSUER164002.0000000WITHHOLD164002.000000AGAINSTS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025AUDIT-RELATEDISSUER164002.0000000FOR164002.000000FORS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER164002.0000000FOR164002.000000FORS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Advisory vote to approve the frequency of future advisory votes to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER164002.0000000ONE YEAR164002.000000FORS000002106Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Jeff AjerDIRECTOR ELECTIONSISSUER1031632.0000000FOR1031632.000000FORS000002106Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Chris Cain, Ph.D.DIRECTOR ELECTIONSISSUER1031632.0000000FOR1031632.000000FORS000002106Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Sarah Gheuens, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1031632.0000000FOR1031632.000000FORS000002106Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER1031632.0000000FOR1031632.000000FORS000002106Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1031632.0000000FOR1031632.000000FORS000002106Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including increasing the number of shares available for issuance thereunder by 8,000,000 shares.COMPENSATIONISSUER1031632.0000000AGAINST1031632.000000AGAINSTS000002106Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To approve the Viridian Therapeutics, Inc. 2025 Employee Stock Purchase Plan.COMPENSATIONISSUER1031632.0000000FOR1031632.000000FORS000002106CyberArk Software Ltd.M2682V108IL001133446806/24/2025Reelect Gadi Tirosh as DirectorDIRECTOR ELECTIONSISSUER407876.0000000FOR407876.000000FORS000002106CyberArk Software Ltd.M2682V108IL001133446806/24/2025Reelect Amnon Shoshani as DirectorDIRECTOR ELECTIONSISSUER407876.0000000FOR407876.000000FORS000002106CyberArk Software Ltd.M2682V108IL001133446806/24/2025Reelect Avril England as DirectorDIRECTOR ELECTIONSISSUER407876.0000000FOR407876.000000FORS000002106CyberArk Software Ltd.M2682V108IL001133446806/24/2025Approve Grant of Equity Based Compensation to Matthew Cohen, CEOCOMPENSATIONISSUER407876.0000000FOR407876.000000FORS000002106CyberArk Software Ltd.M2682V108IL001133446806/24/2025Approval of an Equity Incentive Plan for the Years 2025-2027, to Ehud (Udi) Mokady, the Company's Executive ChairmanCOMPENSATIONISSUER407876.0000000FOR407876.000000FORS000002106CyberArk Software Ltd.M2682V108IL001133446806/24/2025Approve Amended Compensation Policy for the Executives and Directors of the CompanyCOMPENSATIONISSUER407876.0000000FOR407876.000000FORS000002106CyberArk Software Ltd.M2682V108IL001133446806/24/2025Reappoint Kost Forer Gabbay & Kasierer as Auditors and Authorize Board to Fix Their RemunerationAUDIT-RELATEDISSUER407876.0000000FOR407876.000000FORS000002106IDEAYA Biosciences, Inc.45166A102US45166A102506/24/2025To elect two Class III directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: Jeffery L. Stein. Ph.D.DIRECTOR ELECTIONSISSUER1431888.0000000FOR1431888.000000FORS000002106IDEAYA Biosciences, Inc.45166A102US45166A102506/24/2025To elect two Class III directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: Scott W. MorrisonDIRECTOR ELECTIONSISSUER1431888.0000000FOR1431888.000000FORS000002106IDEAYA Biosciences, Inc.45166A102US45166A102506/24/2025To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER1431888.0000000FOR1431888.000000FORS000002106IDEAYA Biosciences, Inc.45166A102US45166A102506/24/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders.SECTION 14A SAY-ON-PAY VOTESISSUER1431888.0000000FOR1431888.000000FORS000002106Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Jennifer GoodDIRECTOR ELECTIONSISSUER363918.0000000FOR363918.000000FORS000002106Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Edward T. MathersDIRECTOR ELECTIONSISSUER363918.0000000WITHHOLD363918.000000AGAINSTS000002106Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER363918.0000000FOR363918.000000FORS000002106Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER363918.0000000FOR363918.000000FORS000002106Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law of the State of Delaware (the "Officer Exculpation Proposal").CORPORATE GOVERNANCEISSUER363918.0000000FOR363918.000000FORS000002106Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Officer Exculpation Amendment.CORPORATE GOVERNANCEISSUER363918.0000000AGAINST363918.000000AGAINSTS000002106Affirm Holdings, Inc.00827B106US00827B106106/25/2025To approve the reincorporation of the Company from the State of Delaware to the State of Nevada by conversion.EXTRAORDINARY TRANSACTIONSCORPORATE GOVERNANCEISSUER519218.0000000AGAINST519218.000000AGAINSTS000002106Affirm Holdings, Inc.00827B106US00827B106106/25/2025To approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve Proposal No. 1.CORPORATE GOVERNANCEISSUER519218.0000000AGAINST519218.000000AGAINSTS000002106Arvinas, Inc.04335A105US04335A105106/25/2025Election of three Class I directors: Linda BainDIRECTOR ELECTIONSISSUER1946507.0000000FOR1946507.000000FORS000002106Arvinas, Inc.04335A105US04335A105106/25/2025Election of three Class I directors: John Houston, Ph.D.DIRECTOR ELECTIONSISSUER1946507.0000000FOR1946507.000000FORS000002106Arvinas, Inc.04335A105US04335A105106/25/2025Election of three Class I directors: Laurie Smaldone Alsup, M.D.DIRECTOR ELECTIONSISSUER1946507.0000000FOR1946507.000000FORS000002106Arvinas, Inc.04335A105US04335A105106/25/2025To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1946507.0000000FOR1946507.000000FORS000002106Arvinas, Inc.04335A105US04335A105106/25/2025Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1946507.0000000FOR1946507.000000FORS000002106Kymera Therapeutics, Inc.501575104US501575104406/25/2025To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shareholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Jeffrey Albers, J.D., MBADIRECTOR ELECTIONSISSUER2770629.0000000FOR2770629.000000FORS000002106Kymera Therapeutics, Inc.501575104US501575104406/25/2025To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shareholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Felix J. Baker, Ph.D.DIRECTOR ELECTIONSISSUER2770629.0000000FOR2770629.000000FORS000002106Kymera Therapeutics, Inc.501575104US501575104406/25/2025To approve, on a non-binding advisory basis, the compensation of our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER2770629.0000000FOR2770629.000000FORS000002106Kymera Therapeutics, Inc.501575104US501575104406/25/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER2770629.0000000FOR2770629.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/26/2025Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER2029345.0000000FOR2029345.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/26/2025Approve Remuneration ReportCOMPENSATIONISSUER2029345.0000000FOR2029345.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/26/2025Approve Remuneration PolicyCOMPENSATIONISSUER2029345.0000000AGAINST2029345.000000AGAINSTS000002106Autolus Therapeutics Plc05280R100US05280R100506/26/2025Reappoint Ernst & Young LLP as Auditors and Authorize Their RemunerationAUDIT-RELATEDISSUER2029345.0000000FOR2029345.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/26/2025Elect Director Robert IannoneDIRECTOR ELECTIONSISSUER2029345.0000000AGAINST2029345.000000AGAINSTS000002106Autolus Therapeutics Plc05280R100US05280R100506/26/2025Elect Director Ravi RaoDIRECTOR ELECTIONSISSUER2029345.0000000FOR2029345.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/26/2025Approve Qualified Employee Stock Purchase PlanCOMPENSATIONISSUER2029345.0000000FOR2029345.000000FORS000002106Praxis Precision Medicines, Inc.74006W207US74006W207006/26/2025To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Jeffrey Chodakewitz, M.D.DIRECTOR ELECTIONSISSUER352960.0000000FOR352960.000000FORS000002106Praxis Precision Medicines, Inc.74006W207US74006W207006/26/2025To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Merit Cudkowicz, M.D.DIRECTOR ELECTIONSISSUER352960.0000000FOR352960.000000FORS000002106Praxis Precision Medicines, Inc.74006W207US74006W207006/26/2025To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER352960.0000000FOR352960.000000FORS000002106Praxis Precision Medicines, Inc.74006W207US74006W207006/26/2025To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTESISSUER352960.0000000AGAINST352960.000000AGAINSTS000002106Revolution Medicines, Inc.76155X100US76155X100006/26/2025To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Frank K. Clyburn, Jr.DIRECTOR ELECTIONSISSUER1677815.0000000FOR1677815.000000FORS000002106Revolution Medicines, Inc.76155X100US76155X100006/26/2025To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Sandra J. Horning, M.D.DIRECTOR ELECTIONSISSUER1677815.0000000FOR1677815.000000FORS000002106Revolution Medicines, Inc.76155X100US76155X100006/26/2025To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Sushil Patel, Ph.D.DIRECTOR ELECTIONSISSUER1677815.0000000FOR1677815.000000FORS000002106Revolution Medicines, Inc.76155X100US76155X100006/26/2025To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Thilo Schroeder, Ph.D.DIRECTOR ELECTIONSISSUER1677815.0000000FOR1677815.000000FORS000002106Revolution Medicines, Inc.76155X100US76155X100006/26/2025To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025; andAUDIT-RELATEDISSUER1677815.0000000FOR1677815.000000FORS000002106Revolution Medicines, Inc.76155X100US76155X100006/26/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER1677815.0000000FOR1677815.000000FORS000002106